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THERAPEUTIC POTENTIAL OF WITHAFERIN-A AGAINST NON-SMALL CELL 
LUNG CANCER:  
Al Hassan Kyakulaga 
August 29th, 2019 
            Lung cancer remains the leading cause of cancer-related deaths among both men 
and women worldwide, and in the United States. Non-small cell lung cancer (NSCLC) 
represents about 85-90% of all lung cancer cases and has an overall five-year survival 
rate of only 17%. Since 60-70% of NSCLC patients are diagnosed when the tumors are at 
an advanced stage, chemotherapy remains the most viable treatment option for NSCLC. 
Recently, the development of molecularly targeted drugs and the breakthrough 
immunotherapies have shifted the front-line therapies for NSCLC from cytotoxic 
chemotherapy towards an era of personalized medicine. However, due to the high genetic 
and cellular heterogeneity of NSCLC tumors, these revolutionary therapies are not 
applicable in >70% of NSCLC patients. Moreover, regardless of treatment approach, 
dose-limiting toxicity and drug resistance are major therapeutic challenges in treatment of 
advanced NSCLC. Therefore, there is a significant unmet clinical need to develop highly 
efficacious therapeutic options for the treatment of advanced NSCLC. In this dissertation, 
studies were performed with the overall objective of determining the therapeutic potential of 
withaferin A (WFA), a plant-derived steroidal lactone anticancer compound against NSCLC.  
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Briefly, the preclinical efficacy, toxicity and pharmacokinetic properties of WFA were 
investigated using in vitro and in vivo models. Two human NSCLC cell lines, H1299, and 
A549 were used to investigate the antitumor efficacy of WFA, alone or in combination with 
paclitaxel (PAC), a standard chemotherapeutic agent used for the treatment of various types 
of cancer. Firstly, we found that WFA alone significantly inhibited (IC50: 0.3-0.6 µM) the 
growth, proliferation, colony formation, adhesion,  migration, and invasion of both H1299 
and A549 cells. As reported elsewhere, the antitumor activities of WFA were both time- and 
concentration-dependent, but were completely abrogated in the presence of thiol-containing 
compounds such as N-acetyl cysteine (NAC) and dithiothreitol (DTT).  Importantly, the 
combination of PAC and WFA at 1:40, 1:20, and 1:10 ratios, respectively, resulted in 
synergistic inhibition of tumor cell growth and proliferation for both H1299 and A549 cell 
lines. Comparatively, the PAC+WFA combination displayed greater anticancer efficacy and 
potency than cisplatin (cis-Pt) alongside PAC (cis-Pt+PAC) or cis-Pt+WFA, and it resulted in 
a >40-fold decrease in the IC50 of PAC against both H1299 and A549 cells. In addition, using 
PAC or taxol resistant cell lines (TR-A549), we  demonstrated that WFA was active against 
the growth and proliferation of chemotherapy resistant human NSCLC cells both in vitro and 
in vivo. Mechanistically, WFA induced apoptosis, modulated the expression of MDR-1,  as 
well as inhibited the induction of epithelial-to-mesenchymal transition (EMT) in A549 
NSCLC cells via the regulation of Smad2/3 and NFκB signaling. In the toxicity evaluation, 
we found that oral administration of up to 12 mg/kg of WFA was well tolerated with no signs 
of systemic and histopathologic toxicity in male SD rats. Also, a highly sensitive, 
reproducible and robust HPLC-MS/MS method for the detection and quantification of WFA 
in plasma and tissues was developed. Pharmacokinetically, WFA displayed a high plasma 
protein binding capacity (>95%) and high in vitro intrinsic clearance (Clint: 88µL/min/mg) in 
SD rat liver microsomes. Following a single intravenous bolus dose (10 mg/kg), plasma 
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concentration-time profile of WFA showed a very rapid clearance from plasma (t1/2 = 37 
min). Together, the findings presented in this dissertation demonstrate the therapeutic 
potential of WFA, and provide a strong rationale for the further studies to develop WFA 
alone or its combination with standard chemotherapeutic agents such as PAC for the 
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Lung Cancer               
            Lung cancer is the leading cause of cancer-related deaths among both men and 
women worldwide [1, 2], and in the United States [3]. In 2018, there were about 2.1 million 
new cases (about 11.6% of all cancer cases) and 1.76 million deaths due to lung cancer 
reported worldwide [4]. In the United States, approximately 234,030 new cases (121,680 
men and 112,350 women) and 154,050 deaths (83,550 men and 70,500 women) due to 
lung cancer were estimated to have occured in 2018 [3]. On the basis of these statistics, 
more people have died from lung cancer than from breast, pancreatic, prostate and colon 
cancers combined [3, 5]. This extremely poor prognosis from lung cancer is driven in part 
by the complexity and biological aggressiveness of lung tumors [5-7]. In addition, the 
majority of lung cases are either locally advanced or highly metastatic at the time of 
diagnosis [8] and are never curable regardless of treatment approach [9, 10]. Thus, although 
there have been notable improvements in the progression-free survival rates, the overall 
survival from lung cancer has remained dismal [3]. Therefore, unless new treatments are 
developed, there remains a significant unmet clinical need for the development of clinically 
effective therapeutic strategies to change the current clinical landscape of lung cancer.  
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            Clinically, lung cancer is a highly heterogeneous and complex disease, representing 
a large group of tumor types that develop from cells in the lung tissue [5, 7, 11]. Although 
there are many subtypes, lung tumors almost exclusively (>99%) develop from airway 
epithelial cells [7] and are generally termed as carcinomas. The high tumor heterogeneity, 
coupled with the biological aggressiveness of lung cancer make the treatment choices very 
difficult, subjective and ineffective [9, 11, 12]. As such, to effectively treat these multiple 
lung cancer subtypes is a major challenge which demands a spectrum of treatment options 
and approaches. Additionally, lung tumors are largely asymptomatic in the early stages [6, 
11] and as a result are mostly diagnosed when the disease is at an advanced stage. Thus, 
despite the advancements in imaging techniques and molecular diagnostics, current clinical 
reports indicate that 60-70% of lung cancer cases are diagnosed at stage III-IV [3, 13]. 
Since curative surgery is not applicable in patients with advanced lung cancer, almost all 
stage III-IV lung cancer patients succumb to the disease within a year of diagnosis [9, 13]. 
Unfortunately, even among patients that present with early-stage disease, there are very 
high tumor relapse rates which contribute to high mortality rates [14].  
            Based on the cellular histology (Fig. 1.1), the World Health Organization (WHO) 
classifies lung cancer as either small-cell lung cancer (SCLC) or non-small cell lung cancer 
(NSCLC) [5, 10]. In the US and worldwide, NSCLC tumors account for 80-90% of all lung 
cancer cases [3]. The SCLC tumors primarily occur among heavy smokers and appear as 
small round-shaped tumor cells, with visible mitotic patterns, granular nuclear chromatin 
and absent nucleoli [6, 7]. On the other hand, NSCLC tumor cells are much more complex 
[5] and are further sub-divided into three main subtypes; adenocarcinomas, squamous-cell 
carcinomas and large-cell carcinomas [15]. Currently [5], adenocarcinomas are the most 
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prevalent subtype of NSCLC [2, 10] and these present as glandular or mucin-producing 
cells. Histologically, the appearance of tumor cells in adenocarcinomas is such that the 
cells are arranged as; (a) acinar, (b) papillary, (c) bronchoalveolar, or a mixture of these 
growth patterns (Fig. 1.1) [10]. Contrastingly, the appearance of squamous cell carcinomas, 
the second most prevalent subtype of NSCLC, is such that the cells display intercellular 
bridges and/or keratin. Finally, large-cell carcinomas, the third subtype of NSCLC are 
visualized as large tumor cells containing vesicular nuclei and prominent nucleoli. Overall, 
the high degree of cellular and genetic complexity of lung tumors make treatment options 
extremely challenging and accounts for the poor prognostic outcomes [16, 17]. 
            Etiologically, the carcinogenesis of lung cancer is a complex and multifactorial 
process that is driven by an interplay of several environmental, genetic and lifestyle factors 
[6, 10]. To date, cigarette smoking remains by far the major cause for lung cancer, and 
worldwide statistics [1, 2, 10] show a significant positive correlation between smoking 
patterns and lung cancer incidence rates. These data indicate that both active and side-
stream (or the so called “passive”) smoking cause lung cancer [6, 7]. Quantitatively, the 
risk for lung cancer increases with both the quantity and duration of smoking, and as such 
is highest among those who smoke and never quit. In the United States, it has been 
estimated that almost 90% of all lung cancer cases are attributable to cigarette smoking 
[18] [3]. Chemically, cigarette smoke contains a complex mixture of many known 
carcinogens (such as benzo[a] pyrene and, nitrosamines) [6, 7]. In susceptible individuals, 
exposure to these carcinogens cause specific genetic mutations and/or epigenetic changes 
in cells that result in alteration of cellular-signaling mechanisms. Studies have shown that 
early in the carcinogenic process [6], these changes in cell signaling mechanisms confer a 
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proliferative advantage to a small group of lung epithelial cells that are later progressively 
transformed into highly malignant lung tumor cells [7, 11]. In addition to carcinogens in 
cigarette smoke, other risk factors for lung cancer include exposure to asbestos, chromium, 









Fig 1.1. Histologic classification of Lung Cancer. 
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The NSCLC Staging system 
            The staging of cases at diagnosis is very critical in the treatment of NSCLC. 
Currently, the choice of therapeutic strategy and the expected clinical prognosis for 
NSCLC are mainly dependent on the stage of the disease at diagnosis. The most widely 
utilized and recommended staging criteria for NSCLC tumors at first diagnosis is the 
Tumor-Node-Metastasis (TNM) system (Table 1). In this staging system, the NSCLC 
tumors are assigned a series of descriptors or scores which enable oncologists to group the 
NSCLC tumors into seven clinical stages that reflect the expected clinical outcomes [11]. 
Numerical clinical scores are assigned to the size of the primary tumor (T), the presence of 
tumor metastases in the regional lymph nodes (N) and in distant organs (M) [19, 20]. 
Together, the combination of these scores allows the NSCLC cases to be grouped into the 
seven stages; IA, IB, IIA, IIB, IIIA, IIIB, and V. For prognostic purposes, the NSCLC cases 
assigned to stages IA, IB, IIA, and IIB are  generally considered to be in the early-stages 
of the disease. For these early-stages of NSCLC, the primary tumors are associated with 
no evidence of local or distant metastases [20, 21]. On the other hand, NSCLC cases that 
display tumor descriptors which fall into the stages III-V display evidence of metastatic 
nodules in the regional lymph nodes and/or distant organs. Therefore, the stages III-V of 
NSCLC are considered to be advanced stages of the disease Un and these usually have the 
worst survival outcomes [20]. Unfortunately, in the clinic, the majority of NSCLC cases 
(60-70%) are diagnosed when the tumors are at stage IV-V and are considered to be 




Table 1. The TNM NSCLC Staging System  
 
Stage TNM 
Stage 0 Carcinoma in situ 
Stage 1A T1 N0 M0 
Stage 1B T2 N0 M0 
Stage IIA T1 N1 M0 
 T2 N1 M0 
Stage IIB T3 N0 M0 
 T3 N1 M0 
 T1 N2 M0 
Stage IIIA T2 N2 M0 
 T3 N2 M0 
 T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
Stage IIIB T1 N3 M0 
 T2 N3 M0 
 T3 N3 M0 
 T4 N3 M0 
Stage V Any T, Any N, M1 
  




The Treatment of NSCLC 
           Once the stage of NSCLC is established, the next step is the determination of the 
most appropriate course of treatment for each patient on a case by case basis. In the clinic, 
the treatments for NSCLC comprise of surgical removal of part or whole of the lung tissue, 
radiation, and systemic chemotherapy either alone or in combination [6, 13]. Per the TNM 
descriptors, the therapeutic goal for early-stage NSCLC is to cure the patients of the 
primary tumors. Therefore, for patients that are diagnosed with early stage NSCLC, 
curative surgery is the standard treatment of choice and this patient population represents 
those in whom the best clinical outcomes are expected. Indeed, multiple clinical reports 
have shown that cure of the primary tumors is reportedly attainable in up to 80% and 50% 
for stage I and stage II cases, respectively [13]. Unfortunately, only about 20-25% of all 
NSCLC cases are at an early stage (I-II) at diagnosis [2]. Moreover, many of these patients 
are above 60 years of age and comorbidities such as pulmonary and cardiac disease are not 
uncommon. As such, in greater than 50% of early-stage NSCLC patients, surgery is not 
practical because of the poor overall health condition of the patients or what is clinically 
referred to as performance status [6]. Furthermore, it is also widely reported that relapse 
rates in NSCLC after surgery are in excesses of 70% within 6-12 month. Therefore, surgery 
by itself is never a sufficient and effective therapeutic strategy for the treatment of NSCLC 
and most patients require supportive systemic therapies [13, 18, 22].  
            Systemic chemotherapy remains the cornerstone in the management of NSCLC in 
the neoadjuvant, adjuvant and/or palliative settings. Regardless of the stage of NSCLC at 
diagnosis, almost all NSCLC patients benefit from some form of systemic therapy during 
the course of the treatment. However, since surgery is not option for patients with advanced 
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NSCLC chemotherapy remains the treatment of choice. The main clinical objectives of 
systemic chemotherapy in advanced NSCLC are to; (1) manage the symptoms, (2) prolong 
patient survival, and (3) maintain or improve the patient’s quality of life. Today, the 
systemic therapeutic options for NSCLC fall into three broad categories: (1) platinum-
based combinations, (2) molecularly targeted drugs, and (3) immune checkpoint inhibitors. 
Before the selection of the systemic chemotherapeutic regimen in NSCLC, patients are 
evaluated for several important factors such as tumor histology, patient performance status, 
the presence of metastasis, and the status driver mutations. Given the biological complexity 
of NSCLC tumors, no single systemic treatment has been proven clinically effective and 
as such, the choice of the course of treatment has remained subjective and mainly 
dependent on the toxicity profile of the drugs used. In the current WHO guidelines, 
systemic therapy for NSCLC recommends a combination of multiple drugs with different 
mechanisms of action and therapeutic targets to maximize efficacy, and minimize the risk 
of overlapping toxicities.  
            Previously, the choice of systemic chemotherapy for NSCLC was solely dependent 
on the stage and patient performance status without regard to the differences in the 
histological subtypes. However, two very significant clinical findings transformed the 
treatment choices for the various histological subtypes of NSCLC. Firstly, it was observed 
that the anti-angiogenic agent bevacizumab was differentially toxic among NSCLC with 
different tumor subtypes. Secondly, in multiple clinical trials it was determined that 
pemetrexed, a folate anti-metabolite antitumor agent was ineffective in patients with 
squamous cell carcinoma (SCC), a subtype of NSCLC. Although detailed molecular 
mechanisms have not been elucidated for these observations, together, these two novel 
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clinical findings permanently changed the treatment approaches for the different subtypes 
of NSCLC. Consequently, while adenocarcinoma, squamous cell carcinoma, and large cell 
carcinomas are all NSCLC, they each have slightly variable treatment approaches.  
             In the past decade, the landmark discoveries that revolutionalized the treatment 
approaches for NSCLC were the molecular identification of activating mutations in genes 
such as the EGFR and ALK in adenocarcinomas. The discovery of driver mutations in the 
EGFR and ALK genes have unearthed and fueled the development of new therapeutic 
paradigms for NSCLC in the form of molecularly targeted drugs. Subsequently, we have 
witnessed an evolution of molecularly targeted therapies such as tyrosine kinase inhibitors 
(TKIs) and their accelerated FDA approval as first-line therapies for advanced NSCLC. 
The introduction of TKIs into the clinic have tremendously shifted the therapeutic options 
of NSCLC towards an era of personalized medicine. However, these drugs have also been 
largely ineffective because only 20-30% of NSCLC cases harbor ‘targetable’ driver 
mutations. In addition, besides the high cost of therapy, targeted drugs only offer marginal 
and temporary improvements in clinical response mainly due to the rapid development of 
drug resistance and the widely observed disease progression while on treatment. 
            Specifically, small molecules targeting mutations in the EGFR gene have become 
very popular as frontline treatments for advanced NSCLC adenocarcinomas. In the US, 
EGFR mutations represent approximately 10-15% of adenocarcinoma patients, the most 
prevalent of which is exon 19 deletions and mutations in exon 21. Extensive molecular 
studies have showed that these EGFR pathway-activating mutations promote cellular 
proliferation and the expression of antiapoptotic mechanisms, which together promote 
tumor progression [14, 25]. For such patients, agents targeting EGFR mutations have 
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become the first-line therapies for NSCLC adenocarcinoma. In this class of anticancer 
agents, Gefitinib was the first TKI targeting EGFR mutations to receive accelerated FDA 
approval in 2003 as monotherapy for locally advanced or metastatic NSCLC. Gefitinib was 
found to be highly effective in NSCLC patients with tumors haboring EGFR mutations 
after the failure of both platinum-based and docetaxel therapies. In 2004, another EGFR 
inhibitor, Erlotinib was the first oral anti-EGFR TKI agent to be approved by the FDA for 
the treatment of advanced NSCLC after treatment failure by platinum-based therapies. 
Later, the agents such as afatinib, osmertinib, and rociletinib all of which target EGFR have 
been approved, and alongside gefitinib and erlotinib are recommended as the first-line 
chemotherapeutic agents for the treatment of advanced NSCLC adenocarcinoma with 
EGFR activation mutations. Unfortunately, almost all patients who are treated with these 
anti-EGFR drugs experience disease progression within 2 years [17]. Although patients 
initially show favorable clinical responses, about 50-60% rapidly develop secondary EGFR 
mutations and lose the sensitivity of EGFR TKIs.   
            On the other hand, the American Cancer Society (ACS) estimates that ALK-EML4 
gene fusions are present in about 2-7% of NSCLC patients. In previous clinical trials, it 
was found that patients who harbor ALK rearrangements did not benefit from therapy with 
EGFR TKIs. Subsequently, this led to the development and approval in 2011 of crizotinib, 
an oral ALK inhibitor that produced response rates of up to 57% in ALK-positive cases. 
Thereafter, ceritinib and alectnib, both of which are more potent ALK inhibitors than 
crizotinib, have been approved for the treatment of ALK-positive NSCLC, especially in 
patients with tumors that are resistant to crizotinib. In addition to EGFR and ALK targeting 
drugs, other targeted therapies against HER2 mutations (trastuzumab), BRAF (dabrafenib), 
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RET rearrangements (cabozantinib) and angiogenesis (bevacizumab) are also approved for 
the treatment of advanced NSCLC [17, 25, 26]. 
            The most recent breakthrough therapeutic strategies for the treatment of advanced 
NSCLC are the immunotherapies. These new anticancer agents are mainly premised on the 
restoration of dysregulated immune system responses against cancer cells in patients [27, 
28]. Unlike chemotherapy, immunotherapies indirectly target tumor cells by stimulating 
the individual patient’s immune system mechanisms to attack tumors [6]. In general, there 
are two approaches to immunotherapy of cancer namely, (1) the vaccination and (2) the 
immune-checkpoint approaches. In the vaccination approach, antigens or cells are used to 
stimulate T-cells to eliminate tumor cells. Today, vaccines against EGF, TGFβ, and PD-1 
are at different stages of advanced clinical testing with promising findings and their 
possible introduction to the therapeutic armamentarium against NSCLC in the near future 
[4]. On the other hand, the immune-checkpoint approach utilizes specific monoclonal 
antibodies to neutralize specific tumor molecular pathways [4, 14]. The two most 
prominent drug targets for immune checkpoint inhibitors are: the cytotoxic T-lymphocyte-
associated antigen-4 (CTLA-4) and programmed cell death protein-1 (PDL-1). In 2015, 
pembrolizumab and nivolumab, both of which are monoclonal antibodies, received FDA 
approval for the treatment of metastatic NSCLC. Based on the results of the landmark 
KEYNOTE clinical trials, it has been determined that pembrolizumab is highly effective 
in patients expressing PDL-1 on greater than 50% of tumor cells. Consequently, nivolumab 
and pembrolizumab have become the standard therapeutic strategy for patients with PDL-
1 overexpressing squamous and non-squamous advanced NSCLC. 
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            However, in the greater majority of NSCLC patients, tumors do not show targetable 
driver mutations. For these patients, the first-line systemic therapies are platinum-based 
combination chemotherapies [6]. These treatments are administered as two or more drug 
combinations consisting of a platinum compound  (such as cisplatin or carboplatin) 
alongside a second or third-generation chemotherapeutic agents. Usually, based on the 
patient’s clinical status, four to six cycles are administered while monitoring the clinical 
response and toxicity profile. Today, the most common antitumor agents used alongside 
the platinum drugs are: paclitaxel, docetaxel, gemcitabine, pemetrexed or vinorelbine [18, 
23]. These various drug combinations have been found to show similar clinical efficacies 
and the choice of treatment is mainly dictated by patient factors and toxicity profile [6, 24]. 
Clinically, it appears that the cisplatin-taxane therapies although are associated with greater 
toxicity potential, have consistently provided higher clinical response rates. In many 
treatment guidelines, a two-drug combination of cisplatin and paclitaxel are recommended 
as the standard regimen for stage IIIB-IV lung cancer with 1-year survival rate exceeding 
40% [4, 24]. More recently, because of the lower toxicity profile of gemcitabine, a three-
drug combination (in addition to cisplatin and paclitaxel) has also become popular but with 
minimal increments in overall patient survival [24]. In patients with non-squamous 
carcinoma, pemetrexed is recommended as the third drug to the cisplatin-paclitaxel 
combination and survival rates are between 13-14 months [6]. 
           In summary, the targeted drugs and immunotherapies have revolutionalized the 
systemic therapies for NSCLC. However, platinum-taxane combinations still represent the 
the gold standard in the treatment for advanced NSCLC. Unfortunately, these drugs also 




            Withaferin A (WFA) is a member of a large group of naturally occurring 28 carbon-
containing compounds collectively called the withanolides [19]. These withanolides (Fig. 
1.2) are structurally composed of a steroidal framework to which a lactone ring is attached 
and are sometimes referred to as ‘steroidal-lactones’ [20]. The steroidal part of 
withanolides consists of network of 4-cycloalkane rings, 3-cyclohexane rings, and 1-
cyclopentane ring. The second part of withanolides, the lactone ring, is a cyclic ester which 
is appropriately oxidized to form a 6-membered ring [19]. This overall basic withanolide 
structure can be modified either in the steroid framework or the side chains to yield a 
myriad of compounds.  As such, more than 300 different withanolides have been isolated 
and characterized [21]. Of all these compounds, WFA is the most potent and was the first 
member of the withanolides to be isolated from the Solanaceae species.  
            Chemically, WFA is a 4β, 27-dihydroxy-1-oxo-5β, 6β-epoxywitha-2, 24-dienolide 
and was first isolated from alcoholic extracts of the Indian Ayurvedic medicinal plant 
Withania somnifera [20, 22-24]. The isolation of WFA from W. sominfera was prompted 
mainly by the systematic scientific review of the antitumor activities of Indian Ayurvedic 
medicinal plants of which W. somnifera, which is also known as Ashwagandha, or Indian 
ginseng is a popular medicinal plant in the Ayurvedic system. Traditionally, the different 
parts of W. somnifera are used to prepare various types of herbal formulations. Several 
preclinical studies were conducted demonstrating the anticancer effects extracts of W. 
somnifera (L.). Most notably, Devi et al., showed that intraperitoneal (i.p.) administration 
of alcoholic root extracts of W. somnifera significantly inhibited the growth of sarcoma-
180 xenografts in nude mice [23]. In addition, studies also demonstrated the inhibitory 
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effects of W. somnifera on chemically-induced fibrosarcoma and skin tumors in Balb/C 
mice [25]. These studies provided the rationale and fueled the investigation and isolation 
of the bioactive constituents of W. somnifera, which were found to be the withanolides. In 
1965, the first and major withanolide, WFA was isolated from alcoholic extracts of the 
leaves of W. somnifera. Later, WFA was isolated from other species such as Withania 
aristata, Dunalia spinose and Vassobia breviflora [21, 24].  
            Following the isolation of WFA as a crystalline compound alongside its dihydro-
derivative from leaves of W. somnifera, its partial and final chemical structures of WFA 
were first solved by Lavie et al., [20, 23, 24].  In its basic chemical structure (Fig 1.2), 
WFA is composed of an ergostane framework to which a lactone ring is attached. The 
lactone ring in WFA is a cyclic ester composed of 5-carbon atoms, in which the carbon 
atoms at C-22 and C-26 are oxidized to form a 6-membered ring [26]. This unique 
arrangement of atoms in the WFA structure results in five chemically active functional 
groups. These groups include; the unsaturated ketone ring, a hydroxyl group at C-4, 
epoxide ring between C-5 and C-6, a hydroxyl group at C-27, a 6-carbon lactone ring, and 
an unsaturated carbonyl group [27, 28]. Through these functional groups, WFA has the 
ability to interact with multiple molecular targets, particularly proteins, resulting in several 
pharmacological activities [22, 29]. Currently, review of the literature shows that WFA has 
antitumor, anti-inflammatory, antiangiogenic, cardioprotective, immunomodulatory, 
hepatoprotective, anticonvulsant and anabolic effects [21, 29]. In spite of these multiple 
effects, WFA has attracted significant testing mainly for its anticancer activity [22]. 
            The anticancer activity of WFA has been a subject of interest for many researchers 
around the world. Today, several published studies have explored the antitumor efficacy 
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of WFA using cell culture, xenografts and orthotopic tumor models of multiple human 
cancers [22, 28-30]. In most of these studies, WFA has been found to possess pro-
apoptotic, cytotoxic, anti-invasive and anti-migratory effects against multiple tumor cell 
types. Mechanistically, WFA regulates several molecular targets in tumor cells including 
enzymes, signaling molecules and other proteins crucial to the survival of cancer cells [19, 
29]. Results from structure-activity studies have consistently demonstrated that three 
positions in the WFA structure are critical for its interaction with sulfhydryl groups of 
cysteine residues of proteins [27]. These three positions include; (1) the unsaturated ketone 
(C-3) in the A-ring, (2) the epoxide group at C-5, and (3) the lactone ring [27].  
            Recently, spectral analysis of the WFA structure has revealed that C-3 position in 
the unsaturated A-ring is the main target for thiol group binding [31]. In fact, it has been 
hypothesized that the sulfhydryl groups of cysteine residues react with C-3 via ‘Michael-
Addition’ alkylation type of reactions to form covalent bonds [28, 32]. These type of 
reactions are thought to play a major role in the ability of WFA to inhibit several signaling 
molecules in cancer cells. Furthermore, other studies have demonstrated that the epoxide 
ring between C-5 and C-6 is the most critical for the cytotoxic anticancer effects of WFA. 
For example, in vitro studies have shown that the reaction of WFA and 2-mercaptoethanol, 
which specifically affects the 5,6-epoxide structure, resulted in the loss of anticancer 
activity. Similarly, the incubation of WFA with strong reducing agents like N-acetyl 
cysteine (NAC) and dithiothreitol (DTT) resulted in the loss of the pro-apoptotic activity 
of WFA [33]. In other studies, it has been reported that the loss of unsaturation in the A-
ring caused loss of anti-inflammatory and antiangiogenic effects of WFA [21, 34].  
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            In the preclinical setting, several studies have demonstrated the antitumor effects 
of WFA against various cancer types. Briefly, there is evidence to show efficacy of WFA 
against melanoma, breast, lung, prostate, ovarian, thyroid and gastrointestinal cancers. 
Perhaps, of all these, the most extensively investigated type of cancer for which WFA has 
shown excellent activity is breast cancer. For this canvcer type, multiple lines of evidence 
using different tumor models from independent studies indicate that WFA is proapoptotic 
in estrogen-sensitive (MCF-7) and estrogen-independent (MDA-MB-231) breast cancer 
cells in vitro [35]. To corroborate these in vitro findings, in vivo studies conducted using 
nude mice have reported statistically significant inhibition of the growth of subcutaneous 
MDA-MB-231 xenografts. Similarly, WFA has also attenuated the growth and metastasis 
of orthotopically implanted 4T mouse mammary tumor cells [31, 36]. Furthermore, using 
clinically-relevant transgenic animal models for breast cancer, WFA reportedly inhibited 
more than 50% of palpable tumor growth in MMTV-neu mice [36, 37].  
            In addition to breast cancer, preclinical efficacy for WFA has been demonstrated 
against prostate, ovarian, and cervical cancers. For example, intraperitoneal administration 
of WFA (4-8 mg/kg/day) for 24 days resulted in over 70% inhibition of PC3 subcutaneous 
tumor growth in mouse models [38]. Here, the inhibition of tumor growth by WFA was 
attributed to the inhibition of proteasomal activity and subsequent induction of apoptosis. 
In another independent study, 3-5 mg/kg of WFA administered orally to transgenic mice 
for 39 weeks, inhibited tumorigenesis and metastasis of prostate adenocarcinoma [39]. 
Also, WFA alone or in combination with other drugs has shown excellent efficacy against 
cervical cancer and ovarian cancers. Data from in vitro and in vivo studies indicate that 
WFA has the capability of inhibiting the growth of human cervical cancer cells. It was 
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found out that the antitumor activity of WFA in cervical cancer cells was related to the 
downregulation of the human papillomavirus oncogenes E6/E7, resulting in the induction 
of p53 and apoptosis [40]. More recently, the intraperitoneal administration of WFA alone 
or as a combinatorial agent alongside cisplatin to nude mice bearing A2780 human ovarian 
cancer cell xenografts resulted into 70-80% reduction in tumor growth and complete 
inhibition of metastasis [41-43]. Together, these data demonstrate the potential efficacy of 
WFA against gynecological cancers and further highlight the potential of WFA as a 
potential chemotherapeutic agent. 
            To date, the molecular mechanisms of action underlying the antitumor activity of 
WFA remain elusive. Nonetheless, there is a growing body of molecular mechanistic data 
which provides insights into the molecular targets of WFA in tumor cells. The actions of 
WFA can be summarized based on four (4) major activities of WFA in tumor cells. These 
include (1) proapoptotic effects, (2) antiproliferative activities, (3) antimetastatic and anti-
invasive effects,  and (4) cancer stem cell targeting effects. It has been shown that the 
proapoptotic effects of WFA are mainly mediated via the reactive oxygen species (ROS)-
dependent mechanisms, endoplasmic reticulum (ER) stress-dependent mechanisms, and 
the regulation anti- and pro-apoptotic proteins in tumor cells. On the other hand, WFA’s 
effects on cellular proliferation are mainly mediated via G2/M cell cycle arrest-dependent 
mechanisms, such as the regulation p21 and cyclin-dependent kinases. In summary, current 
available evidence shows that WFA is a multifactorial antitumor compound with the ability 
to interact with a myriad cellular targets. The most plausible hypothesis postulates that the 
antitumor effects of WFA are mediated by molecular mechanisms involving the interaction 
of WFA and cellular proteins via thiol oxidation. 
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1.5 Statement of goals 
            The overall goal of this doctoral thesis was to investigate the therapeutic potential 
of WFA, a plant-derived steroidal lactone against NSCLC. Briefly, studies were designed 
to explore the preclinical antitumor efficacy, toxicity and pharmacokinetic properties of 
WFA. Two human NSCLC cell lines, H1299 and A549 were used to evaluate the in vitro 
and in vivo efficacy of WFA alone or in combination with standard chemotherapeutic drugs 
such as PAC and cis-Pt against the growth and proliferation of human NSCLC cell lines. 
In addition, a PAC-resistant (TR-A549) cell line  was used to explore the potential of WFA 
for targeting drug resistance in NSCLC. Finally, the potential repeated-dosing toxicity and 
pharmacokinetic properties of WFA were investigated in male SD rats to evaluate the 
disposition characteristics of WFA. In order to accomplish these research goals, the 
following specific aims were explored; 
Aim 1. To determine the synergistic effects of WFA alongside PAC on the growth 
and proliferation of human NSCLC cells in vitro.  
Aim 2. To investigate the effects of WFA on epithelial-to-mesenchymal transition 
(EMT) and chemoresistance in human NSCLC cells  
Aim 3. To determine the potential 28-day repeat-dose toxicity and the 
pharmacokinetics properties of WFA in SD rats.  
Overall, the findings from the above studies advance a novel strategy of using WFA 
either alone or in combination with PAC as an effective strategy for targeting human 
NSCLC cells. These studies provide a strong rationale for conducting further studies to 





SYNERGISTIC COMBINATIONS OF PACLITAXEL AND WITHAFERIN A 
AGAINST HUMAN NON-SMALL CELL LUNG CANCER CELLS 
INTRODUCTION 
   Lung cancer remains the leading cause of cancer-related deaths among both men 
and women in the U.S [44]. This extremely poor prognosis is explained in part by three 
main characteristics of lung cancer: a) distant organ metastasis at diagnosis, b) a high 
degree of cellular and genetic diversity, and c) rapid development of drug resistance [15, 
45]. Clinically, NSCLC represents 80-85% of all the cases of lung cancer and has an overall 
five-year survival rate of 15% [17, 46]. The therapeutic options for NSCLC are dependent 
upon the clinical stage at diagnosis [46-48] with surgical resection being the standard of 
care for early-stage NSCLC [49]. In early-stage NSCLC, the cure of the primary tumors is 
usually attainable in up to 80% and 50% for stage I and stage II cases, respectively. 
However, about 60-70% of the NSCLC cases are either locally advanced or extensively 
metastatic at the time of diagnosis [5, 13]. Thus, systemic chemotherapy [14, 50] remains 
the cornerstone therapeutic strategy for the treatment of early-stage and advanced cases of 
NSCLC.  
Decades of clinical trials have demonstrated that the use of chemotherapy relieves 
disease symptoms and improves the quality of life in NSCLC patients [9]. Recently, 
landmark discoveries of driver genetic mutations have fueled the development and FDA
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approval of targeted [9, 51] and immunotherapies [52, 53]. Following the introduction of 
these treatments into the clinic, the frontline therapies for advanced NSCLC have been 
shifted and revolutionized towards an era of personalized medicine [12, 53, 54]. Yet, 
besides their high cost, the targeted drugs and immunotherapies only benefit small and 
specific groups of NSCLC patients. This is primarily true because less than 30% of all 
NSCLC patients show targetable mutations [55], and anti-PD-1 drugs are only effective 
among patients with tumors expressing PDL-1 on >50% of tumor cells [56]. Therefore, 
despite these recent therapeutic advancements, NSCLC remains largely incurable, and the 
overall clinical benefit of current therapies in NSCLC is marginal and temporary [46, 48].  
   Platinum-based therapies are the first-line regimens used for neoadjuvant, adjuvant 
and in the palliative setting for advanced NSCLC [16, 57]. Upon diagnosis, NSCLC 
patients with no targetable driver mutations are usually administered with four-six cycles 
[57] of platinum-based chemotherapy. Two platinum compounds, cisplatin or carboplatin 
are used as the main drugs used to treat advanced NSCLC. These platinum compounds 
have nonspecific mechanisms of action [58] and induce apoptosis in both tumor and normal 
cells via the formation of DNA adducts. Mechanistically, cisplatin or carboplatin passively 
diffuses into cells and once inside the cell, one chloride ion is removed from the platinum 
compound and is replaced by a water molecule. Then, the hydrated platinum agent enters 
the nucleus, where it forms strong covalent bonds with purine bases, particularly guanine 
in DNA. The binding of the cisplatin or carboplatin with guanine residues creates 
intrastrand crosslinks, which cause extensive unrepairable DNA damage, and subsequently 
induce apoptosis. Of the two platinum drugs, cisplatin shows the highest antitumor efficacy 
but produces the most significant toxicity in the form of nephrotoxicity as well as the 
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irreversible and often untreatable neurotoxicity. Although effective as monotherapies, 
platinum drugs are administered as combination chemotherapy alongside a third-
generation chemotherapeutic agent [13, 14, 16, 57]. 
   The two-drug taxane-platinum chemotherapeutic combinations represent the 
standard of care as platinum-based systemic treatments for advanced NSCLC [9, 59]. 
Taxanes as a novel class of anticancer agents is a large group of compounds that target 
microtubules inhibiting spindle formation and blockade of mitosis during cell division [60]. 
Paclitaxel (PAC), the most prominent taxane, was first isolated from extracts of the bark 
of Taxus brevifolia (Pacific Yew Tree) in 1964. Unlike other tubulin inhibitors, PAC’s 
mode of action [61] involves the binding to and preventing microtubule disassembly, thus 
causing mitotic arrest, and the induction of apoptosis. In NSCLC, PAC displays greater 
antitumor potency than cisplatin (cis-Pt) against all subtypes NSCLC [14]. Unfortunately, 
since PAC displays variable clinical pharmacokinetics, primarily due to its hydrophobicity, 
it requires large doses. Thus, although highly efficacious, the cis-Pt+PAC chemotherapy 
suffers dose-limiting toxicity and the clinical efficacy has plateaued at about 10 – 14 
months.  
   In the present study, we tested a novel therapeutic strategy to enhance the antitumor 
efficacy of PAC against NSCLC cells through combination with withaferin A (WFA). 
WFA (Fig. 1a),  a member of the withanolides, is a plant-derived anticancer compound that 
was first isolated [23] from extracts of the Indian Ayurvedic medicinal herb, Withania 
somnifera (Ashwagandha). In the recent past, WFA has attracted significant preclinical 
testing [22] mainly for its antitumor activity against lung [40, 62-65], breast [31, 35, 37], 
uterine and cervix [66], ovarian [43], pancreatic [67], B-cell lymphoma [68]. In the present 
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study, we have demonstrated that at various combinatorial ratios, WFA alongside PAC is 
highly synergistic against the growth and proliferation of human NSCLC cells. 
Specifically, our data indicated that PAC+WFA synergistically inhibited colony formation, 
migration, invasion and induced apoptosis in both drug-sensitive and drug-resistant human 
NSCLC cells. When combined, WFA caused a dramatic increase in the efficacy and 
potency PAC against both H1299 and A549 cells. Using the combination index (CI) and 
dose-reduction index values, we found PAC+WFA to be more synergistic than PAC+cis-
Pt or cis-Pt+WFA. In fact, we achieved up to a 40-fold reduction in the IC50 of PAC at a 
1:40 constant ratio of PAC to WFA. In summary, this study demonstrates the potential 
therapeutic efficacy of WFA alone, and in combination with PAC against NSCLC cells 





MATERIALS AND METHODS 
Drugs, chemical supplies, and reagents 
          Withaferin A (purity, > 95%) was provided as a gift sample by 3P Biotechnologies 
(Louisville, KY, USA), paclitaxel (Cat # P-9600) was purchased from LC laboratories 
(Woburn, MA, USA), cisplatin (cis-diamine platinum [II] dichloride, Cat # P4394) and 
2.3% crystal violet solution (Cat # HT90132) were purchased from Sigma Aldrich (St. 
Louis, MO, USA). MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, 
Cat #L11939 ) was purchased from Alfa Aesar (Ward Hill, MA, USA) while dimethyl 
sulfoxide (DMSO, Cat #13390) was purchased from Electron Microscopy Sciences 
(Hatfield, PA, USA). Dulbecco’s Modified Eagle’s Medium (DMEM, Cat #10569044), 
RPMI medium 1640 (Cat # 11875-095), 0.25% Trypsin-EDTA (Cat # 25200-072), 
antibiotics (100 U penicillin/100 mg streptomycin, Cat# 15140), and ultrapure distilled 
water (Cat #10977-015) were purchased from Life Technologies (Grand Island, NY, USA). 
Heat-inactivated fetal bovine serum (FBS, Cat# 12306C)) was purchased from SAFC (St. 
Louis MO, USA). Pierce RIPA cell lysis buffer (Cat #89901), 100x halt 
protease/phosphatase inhibitor cocktail (Cat #7844), Pierce BCA protein assay kit (Cat 
#23225), PVDF-transfer membrane (Cat#88518), Spectra Multicolor broad range protein 
ladder (Cat #26634) and Pierce ECL Western Blotting Substrate (Cat # 32106) were 
purchased from ThermoScientific (Rockford, IL, USA). Bolt 4-12% Bis-Tris phosphate 
gels (Cat #NW04125Box, NW04120Box, NW04122Box) and 20x Bolt MES running 
buffer (Cat# B002) were purchased from Life Technologies (Carlsbad, CA, USA). The 
FITC-AnnexinV/PI Apoptosis Assay kit (Cat#V13242) was purchased from Life 
Technologies (Eugene, OR, USA). Primary monoclonal antibodies (against β-actin, PARP, 
 24 
 
P21, Bcl2, Bax, phospho-histone3, phospho-cdc2, cyclin E2, cyclin B1, cyclin A1, cleaved 
–caspase 3, cleaved-caspase-7, cleaved-PARP) as well as secondary antibodies (anti-
mouse IgG and anti-rabbit IgG) were purchased from Cell Signaling Technology, Inc. 
(Danvers, MA).  
Cell lines and culture conditions. 
            The human NSCLC cell lines, H1299, and A549 cells were obtained from 
American Type Culture Collection (Manasa, VA, USA). Previously developed [69, 70] 
PAC- resistant NSCLC cells (TR-A549) were kindly provided by Dr. Bruce Zetter (Boston 
Children’s Hospital, Boston, MA, USA). These cell lines were maintained in either DMEM 
or RPMI 1640 culture media (10% FBS, 1% antibiotics) for A549 and H1299 cells, 
respectively. The cultures were incubated at 37°C in a 5% CO2 humidified incubator and 
passaged at 80% confluence for less than 20 cycles.  
Drugs and treatments. 
            Stock solutions of PAC, WFA, and cis-Pt at concentrations of 5 mM were prepared 
by dissolving in 100% DMSO at 25 °C. The stock solutions for each drug were stored dried 
in aliquots of 40 µL at -20°C until used in subsequent experiments. Cells were incubated 
with the drugs after diluting the stock concentrations of each test agent in cell culture media 
to desired concentrations. In all treatments, DMSO was kept at a maximum of 1% in the 
vehicle and test treated groups.  
MTT cell viability assay.  
            Cell viability was measured using the MTT colorimetric assay. Briefly, A549 or 
H1299 cells were seeded in 96-well plates and incubated at 37°C overnight to allow 
attachment. Following cellular attachment, the cell culture media was discarded and 
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replaced with fresh cell culture media containing different concentrations of drugs/agents. 
These cells were incubated with the drugs for designated periods and then incubated with 
cell culture media containing 0.5 mg/mL MTT reagent solution. After 3 hours, the MTT 
containing media was discarded and the purple formazan crystals in each well were 
solubilized using 200 µL of  DMSO. The absorbance of the resulting solution was 
determined spectrophotometrically by measuring the optical density (OD) at 570 nm. The 
OD values of the solution in the wells containing untreated cells were considered as 100% 
cell growth and used as a reference to calculate the percent growth of other wells. The 
arithmetic mean of 3 technical replicates was calculated at each concentration of PAC and 
WFA alone and in combination to obtain the percent cell viability. Data were expressed as 
meanSD of more than 3 separate experiments. 
Colony formation assay 
            To perform the colony formation assay, H1299 and A549 cells were seeded in 6-
well tissue culture plates at a density of 500 cells/well in 2 mL of medium (10% FBS) and 
incubated in a 37 °C humidified atmosphere containing 5% CO2 for 24 h. The cells were 
then incubated in culture medium containing different concentrations of either PAC or 
WFA, alone and in combination for 24 h.  The drug-containing medium was replaced with 
fresh drug-free medium. After 7 d, the plates were washed with sterile PBS, and the cells 
were fixed using methanol/acetic solution (3:1) for 5 mins and stained with 0.5% crystal 
violet (in methanol) for 15 min. The crystal violet solution was carefully removed, the 
plates were rinsed in a stream of running water and left to air dry at room temperature. The 




Apoptosis analysis by flow cytometry.  
            Apoptosis was detected using the Annexin V/ propidium iodide (PI) assay. Briefly, 
H1299 and A549 cells were treated with PAC, WFA alone, and in combination for 24 h. 
Both floating and attached cells were collected, washed twice with ice-cold PBS and re-
suspended in 100 µL of Annexin-binding buffer at a cell density of approximately 1 x 106 
cells/mL. To each 100 µL of cell suspension, 5 µL of FITC-Annexin V and 1 µL of 100 
µg/mL PI solution was added and incubated for 15 minutes in the dark. After incubation, 
400 µL of Annexin binding buffer was added to each Annexin V/PI stained cell suspension 
and analyzed for fluorescence using a flow cytometer by measuring the fluorescence 
emission at 530 nm and >575 nm. A total of 10,000 cells were counted in each cell 
suspension, and the data were analyzed using FlowJo software (Trista, CA, USA) to obtain 
the percent early and late apoptotic cells.  
Cell migration and motility assays.  
            The wound-healing assay was performed to assess cell migration and motility. This 
was accomplished using the 2-well culture inserts (ibidi®) following the manufacturer’s 
instructions. Briefly, ibidi® culture inserts were placed in 6-well plates and 3 x 105 cells/ml 
were seeded into each of the two chambers of the same insert.  The cells were incubated in 
the inserts for 24-h to obtain confluent monolayers and the inserts were removed to create 
a wound area (gap) between the two cell growth areas. Floating and dead cells were 
removed by washing the cells twice using culture media, then media containing PAC or 
WFA alone and in combination was added. Cellular migration and motility were assessed 
using a bright-field microscope at 0 and 24 h. The migrated cells were photographed using 
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a microphotographic camera, and the cell-covered areas were measured using WimScratch 
software program (Wimasis, Munich, Germany).  
Transwell migration and invasion assay. 
            Cell migration and invasion assays were performed using the transwell culture 
inserts that were pre-coated with or without 40 μL of 3.0 mg/mL Matrigel (BD). H1299 
cells (4 x 104) suspended in 200 µl of the serum-free medium in the presence and absence 
of test agent(s) were seeded onto the upper compartment of the transwell chamber. The 
lower chamber was filled with 600 μL of media supplemented with 10% FBS as an 
attractant to cause cell migration. After 24 h incubation, cells on the upper surface of the 
transwell insert were removed using a cotton swab. The migrated cells at the bottom of the 
insert were fixed using 4% paraformaldehyde, permeabilized using 100% methanol and 
stained using 0.2% toluidine blue (in 1% sodium borate). The number of migrated cells 
were counted under the light microscope.  
Western blot analysis. 
            Whole-cell protein lysates were prepared using RIPA buffer as per the 
manufacturer’s instructions. The total protein concentration was determined using BCA 
assay and an aliquot of 20 µg total cellular protein of each sample was resolved by SDS-
PAGE on 4-12% Bis-Tris gels. The separated proteins were transferred to PVDF 
membranes, and these membranes were blocked using 5% non-fat dry milk in TBST for 1 
h. To determine the relative expression of specific proteins, membranes were first probed 
with primary antibodies followed by the respective HRP-conjugated secondary antibodies. 
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The expression levels of each protein were determined by visualizing the protein bands 
using the chemiluminescent Pierce ECL western blotting reagent.  
Tumor xenograft studies in nude mice 
            Taxol resistant NSCLC cells (TRA549 cells) were used to determine the in vivo 
efficacy of WFA. Female athymic nude (nu/nu) mice (5–6-week old) were purchased from 
Charles Rivers Labs and were maintained in accordance with the Institutional Animal Care 
and Use Committee (IACUC) guidelines. Briefly, TR A549 cells (2.5 × 106 cells/mouse) 
in 100 µL (50:50) of serum-free media mixed with Matrigel matrix  (Becton Dickinson, 
Bedford, MA) were subcutaneously injected into the left flank of each mouse. The mice 
were provided purified AIN-93M diet and water ad libitum. Once the average tumor size 
reached about 80-120 mm3, the mice were randomly divided into 3 groups (n = 5) and 
treated with vehicle, PAC (10 mg/kg divided in 3 doses per week) and WFA (10 mg/kg) 
as 3 doses per week. All treatments for the vehicle control and intervention drug groups 
were done via intraperitoneal injections (i.p) and the tumor volumes were measured twice 
weekly.  
Statistical analysis.  
            Statistical analysis was performed using Graph Pad Prism 8.0 (La Jola, CA) and 
CalcSyn 2.0 (Biosoft, Cambridge, UK). Data are presented as means ± SD of at least 3 
separate experiments. To determine the synergistic interaction between PAC and WFA, the 
dose-effect data on percent cell viability was analyzed by the combination index (CI) 
method described by Chou et al.[71]. The CI values; CI<1, C=1 and C>1 indicated 




WFA inhibits the proliferation of NSCLC cells via thiol oxidation  
             To determine the antiproliferative effects of WFA alone (Fig. 2.1a) on NSCLC 
cells, we first evaluated its in vitro antitumor effects on monolayers of two human NSCLC 
cell lines.  Briefly, H1299 cells (large cell carcinoma) and A549 cells (adenocarcinoma) 
were seeded in 96-well plates (3000 cells/well) and incubated with WFA (0 – 5 µM) for 3 
- 72 h. The relative cell viability of both cell lines was measured after 72 h incubation by 
the MTT assay. By considering the vehicle treated cells as 100% cell viability, WFA 
significantly decreased the the viability of both H1299 and A549 cells in a dose- and time-
dependent manner (Fig. 2.1b and Fig 2.1c). The median inhibitory concentrations (IC50) 
for WFA as calculated by median-effect equation method using CalcuSyn software were 
in the sub-micromolar range (0.20 - 0.68 µM) for both H1299 and A549 cell lines. The 
efficacy (>90% inhibition) for WFA was observed at when cells were incubated with WFA 
for 48 h and 72h. In either cell lines, the concentrations of WFA  ≥ 2 µM resulted in >90% 
inhibition of cell proliferation at 48 h and 72 h. To support the MTT data, we next examined 
whether WFA induced apoptosis in H1299 and A549 cells. Since we observed using the 
MTT assay that concentrations of WFA ≥2 µM produced maximum efficacy, we chose this 
dose level to investigate the ability of WFA to induce apoptosis. The cells were incubated 
with or without 2 µM WFA for 24 h and apoptosis induction was determined using 
Annexin-V/PI staining assay. Our data (Fig. 2.1d) indicated that WFA when compared to 
the vehicle-treated cells significantly increased the percentage of Annexin V positive cells, 
an indicator of induction of apoptosis. The induction of apoptosis was further confirmed 
by performing western blot analysis (Fig. 2.1e),where we found a dose-dependent increase 
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in the activation (cleavage) of caspase-3, an increase in the expression of p21 and phospho-
Histone 3 (p-H3), all of which were indicative of apoptosis.  
           Previously, studies have reported that the antitumor effects of WFA are dependent 
on the generation of reactive oxygen species (ROS) in tumor cells. Indeed, the role of ROS 
production as regards to the anticancer activity of WFA has been demonstrated in breast, 
ovarian and melanoma tumor cells. Similarly, to further investigate this hypothesis, we 
determined whether or not WFA induced the production of ROS in H1299 and A549 
NSCLC cells. Briefly, cells were seeded in 6-well plates and incubated with 2 µM WFA 
for 12 h. The generation of ROS was qualitatively determined by fluorescence microscopy 
using H2DCFDA (Fig. 2.1f) and Mitosox Red (Fig. 2.1h) assays per manufacturer’s 
instructions. Here, we found that the incubation of cells with WFA (2 µM) increased the 
fluorescence intensity of H2DCFDA (green) and Mitosox Red (red) in both H1299 and 
A549, an indicator of increased production of ROS (Fig. 2.1f and Fig. 2.1h). In this study, 
hydrogen peroxide (H2O2, 100 µM) was used as a positive control. Interestingly, for both 
cell lines, the concomitant treatment of cells with WFA alongside with N-acetyl cysteine 
(2.5 mM) significantly inhibited the production of ROS. To further provide perspective on 
the role of ROS production in the antitumor activity of WFA, we cultured both H1299 and 
A549 cells with WFA in the presence of 3 known ROS quenchers; N-acetyl cysteine 
(NAC), dithiothreitol (DTT) and Trolox. Interestingly, as has been reported elsewhere, the 
thiol-containing compounds NAC (2.5 mM) and DTT (100 µM) completely abrogated the 
anticancer activity of WFA against both H1299 and A549 cells. Contrastingly, Trolox, a 
non-thiol- containing ROS quencher did not inhibit the antiproliferative activities of WFA 





Fig 2.1. WFA inhibits the growth and proliferation of H1299 and A549 NSCLC cells via thiol 
dependent induction of apoptosis. (a) The chemical structure of WFA. The cells were incubated 
with WFA (0-5 µM) for 3, 6, 12, 48 and 72 h and the cell viability measured by MTT assay. WFA 
time and dose-dependently inhibited the proliferation of  H1299 (b) and A549 cells (c). The 
induction of apoptosis following incubation with WFA (2 µM) was determined using annexinV/PI 
assay (d) and western blot analysis (e). Briefly, WFA increased the percentage of annexin V 
positive cells, the clevage of caspase 3, and the expression of p21 and p-H3. The generation of ROS 
was measured the intensity of green fluorescence in the H2DCFDA assay (f) and red fluorescence 
in the Mitosox Red assay (h). H2O2 (100 µM) was used as a positive control and N-acetyl cysteine 
(NAC) was used to inhibit ROS. (g) The antiproliferative activity of WFA was inhibited in the 
presence of thiol donors NAC (2.5 mM) and dithiothreitol (DTT) but not in the presence Trolox.  
Where indicated, data are presented as mean ± SD of 3 technical replicates (*p<0.05). 
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 Synergistic effects of PAC, CisPt, and WFA on NSCLC cellular proliferation  
In this study, we determined the potential synergistic effects of PAC, cis-Pt, and 
WFA in H1299 and A549 cells in vitro. Firstly, we tested each of these agents as individual 
drugs and then based on the relative potency of each compound in the preliminary findings, 
we evaluated synergism using the following combinatorial ratios:  1:40, 1:100, and 10:1 of 
PAC: WFA, PAC:cis-Pt, and cis-Pt: WFA, respectively. In H1299 cells, we demonstrated 
that as individual drugs, PAC, cis-Pt, and WFA each dose-dependently inhibited the 
cellular viability (Fig. 2.2a). By using median-effect plots (Fig. 2.2b), we determined and 
compared the efficacy and potency of the three agents. We found that PAC displayed the 
greatest potency (IC50: 43 nM), followed by WFA (IC50: 251 nM) and then cis-Pt (IC50: 
8438 nM). Based on these data, we next assessed whether the combinations of each drug 
with one of the other two compounds were synergistic against. Using the dose-response 
data (Fig. 2.2d-f) and isobologram analyses (Fig. 2.2g-i), we found that the data points for; 
PAC+WFA, PAC+cis-Pt, and cis-Pt+WFA were all below the lines of additivity at IC50, 
IC75, and IC90. In addition, visual inspection of CI-Fa plots (Fig. 2.2j-l) showed that the CI 
values at various effect levels were all <1. Therefore, as per the method of Chou et al., the 
dose-response data, isobologram and CI values all indicated that three combinations; 
PAC+WFA, PAC+cis-Pt, and cis-Pt+WFA were highly synergistic against H1299 cells,. 
However, based on the dose-reduction index (DRI), we found that there was a 33-fold and 
4-fold reduction in the IC50 of PAC against H1299 cells in the PAC+WFA and PAC+cis-
Pt combinations, respectively. On the other hand, we found a 26-fold and 7-fold change in 
the IC50 of cis-Pt when combined with WFA and PAC, respectively. For WFA, the IC50 
were 5-fold and 8-fold less when combined with PAC and cis-Pt, respectively.  
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Similarly, in A549 cells (Fig. 2.3), we also observed that PAC, cis-Pt, are WFA all 
individually decreased cell viability in a dose-dependent manner. Based on the median-
effect plots (Fig. 2.3b), PAC displayed the lowest IC50 (11 nM), followed by WFA (IC50: 
560 nM) and then cis-Pt (IC50: 5730). In terms of synergism (Fig. 2.3d-l), all combinations 
tested for the 3 drugs resulted in data points at IC50, IC75 and IC90 below the lines of 
additivity, indicating synergistic activity. As was observed in H1299 cells, the combination 
of PAC+WFA resulted in the strongest synergism (PAC DRI: 83-fold) followed by cis-
Pt+WFA (cis-Pt DRI: 22-fold) and PAC+cis-Pt (6-fold and 15-fold DRI for PAC IC50 and 
cis-Pt IC50, respectively). Together, these compelling in vitro data strongly suggested that 
the PAC+WFA combination was the most synergistic chemotherapeutic combination 





Fig 2.2. WFA synergized the antiproliferative activity of PAC and CisPt against H1299 cells. 
The potency and efficacy of PAC, CisPt and WFA against NSCLC cells were compared using the 
median-effect equation. (a) Dose-response plots depicting PAC, CisPt and WFA dose-dependent 
inhibition of cell proliferation of H1299 cells. (b) Median-effect plot indicated PAC had lowest 
IC50 followed by WFA and CisPt the highest. Preliminary combinations of PAC and CisPt, PAC 
and WFA and CisPt and WFA were tested. PAC+WFA (c) displayed the greatest efficacy, followed 
by CisPt + WFA (d).  Isobologram analysis (g-i) and combinaion index (CI) values (<1) indicated 





Fig 2.3. WFA synergized the antiproliferative activity of PAC and CisPt against A549 cells. 
The potency and efficacy of PAC, CisPt and WFA against A549 NSCLC cells were compared 
using the median-effect equation. (a) Dose-response plots depicting PAC, CisPt and WFA dose-
dependent inhibition of cell proliferation of A549 cells. (b) Median-effect plot indicated PAC had 
lowest IC50 followed by WFA and CisPt the highest. Preliminary combinations of PAC and CisPt, 
PAC and WFA and CisPt and WFA were tested. PAC+WFA (c) displayed the greatest efficacy, 
followed by CisPt + WFA (d).  Isobologram analysis (g-i) and combinaion index (CI) values (<1) 
indicated that all the combinations were highly synergistic against A549 cells. 
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Synergistic effect of PAC and WFA on colony formation and induction of apoptosis  
  Next, to validate the observed MTT data, we sought to investigate potential 
synergistic effects of PAC and WFA on the replicative ability of H1299 and A549 cells 
using colony formation assay (Fig. 2.4). Briefly, cells (500 cells/well) were seeded in 6-
well plates and incubated in media containing PAC (0-25 nM) and WFA (0-1 µM) alone, 
or their combination. As expected, PAC and WFA individually displayed dose-dependent 
inhibition of colony formation in H1299 (Fig. 2.4a) and A549 (Fig. 2.4b) cells. As 
expected, the combination of PAC and WFA synergistically inhibited colony formation in 
both cell lines greater than either agent used alone. Our data (Fig. 2.4 c-e), indicated that 
at shorter drug exposure durations resulted in much greater synergistic effects for PAC and 
WFA than was observed when cells were exposed to drugs for extended drug periods (48, 
72 h).  
Further, we investigated whether the PAC + WFA combination induced apoptosis in 
NSCLC cells. Cells were incubated with WFA (1.0 μΜ) or PAC (25 nM), alone and in 
combination for 24 h, and apoptosis was detected by flow cytometry using the Annexin 
V/PI assay. We found that the combinations of PAC and WFA significantly increased the 
percentage of Annexin-V positive cells (Fig. 2.4f). To support these findings, western blot 
was performed and the data obtained (Fig. 2.4g) indicated an increase in the cleavage of 
both PARP and caspase-3, Bcl-2 degradation, and Bax upregulation. In addition, p21 and 
phospho-H3 were found to be significantly increased, an indication of cell cycle arrest and 




The effect of different ratios, treatment schedules, sequence and cell numbers on the 
synergism of PAC and WFA  
          As we found that PAC+WFA resulted in greater synergism than PAC+cis-Pt or cis-
Pt+WFA against both H1299 and A549 cells, we further examined whether different 
combination ratios, cell numbers, sequences and schedules of treatment would alter the 
synergism. First, we used PAC as the standard of care and then altered the concentrations 
of WFA to test the effects of different ratios of PAC: WFA on cell viability. Based on 
previously obtained IC50 values, we tested combinations of PAC+WFA at 1:40, 1:20, and 
1:10 ratios of PAC to WFA, respectively, on the viability of cells. For each of these ratios, 
we examined the resulting CI and DRI values to assess the extent of synergism. Using 
isobolograms, CI and DRI values, we found that all the ratios 1:40, 1;20, and 1:10 were 
synergistic against both H1299 and A549 cells. For all the combinatorial ratios, the CI 
values at 50% (ED50), 75% (ED75) and 90% (ED90) effect levels were all <1 indicating 
synergism as per Chou et al.,. Since the 1:40 ratio of PAC: WFA produced the lowest 
combined IC50 against both H1299 (3.6 nM) and A549 (7 nM), this combination was 
concluded to have displayed the greatest potency and efficacy of PAC and WFA. In terms 
of synergism, the highest synergistic interaction was displayed by the ratio of 1:10 of 
PAC:WFA since it resulted in the lowest CI values compared to 1:20 and 1:40 (Table 2.1 
and Table 2.2).  
            Next, we determined the most effective strategy for combining PAC and WFA to 
maximize the synergism. We assessed the resultant synergism obtained when the cells were 
exposed to both drugs; (1) concomitantly, (2) sequentially, and (3) in a schedule-dependent 
manner. Firstly, and as expected, all the three treatment strategies (concomitant, sequential 
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and schedule dependence) resulted in synergism of PAC and WFA against both H1299 and 
A549 cells (Table 2.3). Importantly, we found that by pretreatment of cells with WFA (2 
h) prior to incubation with PAC+WFA, the resultant synergism (CI=0.22 and 0.26 for 
H1299 and A549 cells, respectively) was greater than that observed when cells were 
pretreated with PAC prior to PAC+WFA (CI= 0.87 and 0.64) or the simultaneous of PAC 
and WFA treatment (CI: 0.77 and 0.81). Interestingly, the synergism of PAC and WFA 
was not schedule-dependent as there were no significant differences in the potency and 
efficacy of either compounds when the drugs were added in a schedule-dependent manner. 
Furthermore, we determined and compared the CI and DRI values obtained when cells 
were incubated with PAC and WFA for various periods of time.  
          Further, we tested for the effects of PAC and WFA, alone and in combination on 
different cell numbers of H1299 and A549 cells. Briefly; 2000, 4000, 8000 and 12000 
cells/well were seeded in 96-well plates and incubated with increasing concentrations of 
PAC and WFA, alone and in combination (Fig 2.5). The media containing drugs was 
discarded after 12 h and the cells were incubated for up to 48 h to determine cell viability. 
For both H1299 and A549 cell lines, there was a dramatic decrease in the individual 
efficacy of PAC or WFA with an increase in the number of cells plated. As expected, the 
lowest IC50 values for PAC and WFA were observed when incubated with 2000 cells/well 
(Fig 2.5a and Fig 2.5e). However, when the cell numbers were increased to 12000 
cells/well (Fig 2.5d and Fig. 2.5h), there was up to 40-fold and 8-fold increase in the IC50 
of PAC and WFA, respectively against both H1299 and A549 cells. Interestingly, while 
there was an increase in the combined IC50 values of PAC and WFA, there were no 
significant changes in the CI values at various cell numbers. Thus, we concluded that 
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increasing the cell numbers of H1299 and A549 did not alter the synergism between PAC 
and WFA.   
  
Table 2.1. Synergism Summary Table for PAC and WFA on H1299 Cells 
Table 2.2. Synergism Summary Table for PAC and WFA on A549 Cells 
Note: CI: Combination index, Dm: Median dose, m: shape of curve, r: goodness of fit 





Fig 2.4. The combination of PAC and WFA significantly increased efficacy against colony 
formation, proliferation and induction of apoptosis in NSCLC cells. Representative images 
showing the colony formation assay in  H1299 (a) and  A549 (b) cells incubated with PAC and 
WFA alone and in combination. In both cell lines, PAC and WFA alone dose-dependently inhibited 
colony formation. However, the combination of PAC and WFA resulted in much greater inhibition 
of colony formation than either drug alone. Cells were also treated with PAC and WFA for  12 h 
(c), 24 h (d) and  48 h (e) and it was established that the synergism between PAC and WFA was 
greatest at the 12 h incubation time point. (f) Annexin V/PI assay and (g)western blot analysis 
depicted increased apoptosis induction. Moreover, the combination of PAC and WFA increased 





Fig 2.5. Increasing cell numbers did not alter the synergism of PAC and WFA against NSCLC 
cells. H1299 and A549 cells were plated at indicated densities and incubated with PAC and WFA 
alone, and in combination for 48 h. The efficacy and potency of PAC and WFA alone was greatly 
diminished with increasing cell number in both H1299 (a-d) and A549 cells (e-h). However, the 
combination of PAC and WFA synergistically inhibited the proliferation of both cell lines 
regardless of the number of cells plated. Cell viability was measured by MTT assay, fractional 
effects and synergism were assessed by combination index (CI <1) as per as per Chou et al.  
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Effect of the  PAC+WFA combination on migration and invasion of NSCLC cells. 
            Cell motility, migration, and invasion are all important steps that are critical for the 
metastatic dissemination of NSCLC cells. Therefore, we investigated the effects of PAC 
and WFA, alone and in combination, on these cellular events. To determine effects on cell 
migration, we used the wound healing assay to assess the effects of PAC and WFA on cell 
motility into cell-free areas. Representative images (Fig 2.6)were obtained using a light 
microscope to monitor the wound areas between 0 and 24 h in order to determine the rate 
of cell motility. Low doses of PAC and WFA alone, inhibited the motility of H1299 (Fig. 
2.6a) and A549 (Fig. 2.6b) cells. Comparatively, H1299 cells displayed greater migratory 
potential (>90% migration in 24 h) than A549 cells, thus the greatest effects on cellular 
migration for PAC and WFA were observed with A549 cells than H1299 cells. In both cell 
lines, at the tested concentrations, WFA displayed greater inhibitory effects on cell motility 
than PAC. However, the combination of PAC and WFA resulted in much greater inhibition 
of cellular motility than either PAC or WFA alone (<10%, **p<0.01). Furthermore, using 
the trans-well migration and invasion assays, we showed that PAC or WFA alone 
decreased migration and invasion compared to vehicle alone (Fig. 2.6c).  As was observed 
in the motility assay, the combination of PAC and WFA also significantly inhibited cell 
migration than either drug used individually. In summary, the combination of PAC and 
WFA not only synergistically inhibited cellular growth and proliferation, but also 






Fig 2.6. PAC and WFA inhibited NSCLC cell motility and migration. H1299 (a) and  A549 (b) 
cells were incubated with PAC (5 nM) and WFA (0.2 µM) alone, and in combination. Cell motility 
was assessed by wound healing assay over 24 h. Pictures of wound areas were taken using a light 
microscope and analysis by Wimasis software. (c) Invasion assay depicting the synergistic 




WFA targets PAC resistant TRA549 NSCLC cells in vitro and in vivo.  
             Previously published studies have reported that PAC treatment is associated with 
the induction and development of chemoresistance in NSCLC cells [72-74]. For example, 
Davi et al [75] have shown that PAC-resistance was developed in human NSCLC cell lines 
by culturing these cells for >4 months in the presence of increasing concentrations of PAC 
or cis-Pt. In the present study, we used PAC-resistant cells (TR-A549 cells) that were 
developed as described previously (Fig. 2.7a) [69] and kindly provided as a gift by Dr. 
Bruce Zetter (Harvard Medical School). Briefly, these TR-A549 cells were developed by 
starting PAC treatments ½ PAC IC50 concentrations for 2 d followed by culturing the 
surviving cells in drug-free media for 2 wks [70]. In subsequent cycles, the last PAC 
concentration of the previous cycle was increased 2-fold until the development of 
chemoresistance. The taxol-sensitive parental (TS-A549 cells) and taxol-resistant variants 
(TR-A549 cells) were characterized for their drug response to PAC until we observed a 10-
fold change in IC50.  In our studies, (Fig. 2.7b) we evaluated the sensitivity of both the drug-
sensitive and drug-resistant cells to PAC. Using the MTT and colony formation assays, we 
found that the PAC-resistant cells (TR-A549 cells) displayed cross-resistance between 
PAC and cis-Pt but remained sensitive to WFA (Fig. 2.7c-d). Consistent with previous 
studies [75], we detected increased levels of mRNA and protein expression of MDR1 and 
PDL-1 in the drug-resistant NSCLC cells (Fig. 2.7 e-f).   
             To evaluate the response of PAC-resistant TR-A549 cells to WFA, we explored 
the antitumor effects of WFA on the growth and proliferation of TR-A549 cells both in 
vitro and in vivo (Fig. 2.8). First, using in vitro assays, we demonstrated that both the 
parental cells (TS A549) and drug-resistant variants (TR-A549) remained sensitive to WFA 
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in vitro (Fig 2.8a). To determine the effects of WFA on PAC-resistant cells in vivo, we 
established subcutaneous xenografts of PAC resistant cells in mice. WFA (10 mg/kg) was 
administered intraperitoneally in 3 doses per week in athymic nude mice xenografted with 
2 x 106 TR-A549 cells/mouse (Fig. 2.8b). In agreement with in vitro data, mice treated with 
PAC (10 mg/kg divided into 3 doses a week) did not show any difference in tumor volume 
compared to those treated with vehicle. However, WFA significantly and time-dependently 
decreased the average tumor volumes of TRA549 xenografts when compared to vehicle 
and PAC groups. Mechanistically, WFA inhibited the mRNA and protein expression of 
MDR1 in TR A549 cells (Fig. 2.8c); however, modulation of PD-L1 with WFA remains to 
be determined. Therefore, our data presented here show that in addition to synergizing the 
effects of PAC, WFA targets both drug-sensitive and drug-resistant NSCLC cells. As such, 
the ability of WFA to synergize the anticancer efficacy of PAC and cis-Pt in drug-sensitive 
NSCLC cells, and target both drug-sensitive and drug-resistant NSCLC cells provides a 







Fig 2.7. PAC treatment induced MDR1-dependent chemoresistance in NSCLC cells. (a) A549 
cells were incubated in media with or without sub-cytotoxic concentrations of PAC (>6 months). 
(b) The cells incubated with PAC became resistant to PAC (TR-A549) while those incubated in 
media without PAC remained sensitive to PAC (TS-A549). (c) Colony formation assay and (d) 
MTT assay indicated decreased sensitivity of TR A549 cells to both PAC and CisPt but the cells 
remained sensitive to WFA. (e-f) Confocal imaging, (f) RT-PCR and western blot analysis 





Fig 2.8. WFA alone inhibited the growth and proliferation of resistant PAC resistant NSCLC 
cells. (a) MTT assay depicting the in vitro inhibition of cellular proliferation of TR A549 and TS 
A549 (b) WFA significantly inhibited the growth of TR A549 (2.5 x106 cells/mouse) tumor 
xenografts in athymic nude mice. (c) RT PCR and western blot analysis indicated dose-dependent 
inhibition of the expression MDR1 in TR A549 after incubation with WFA for 48 h. (d-e) 
AnnexinV/PI assay indicated dose-dependent induction of apoptosis in TR A549 cells after 
incubation with WFA (0-2µM) for 24 h. (f) Western blot analysis confirmed the induction of 
apoptosis as indicated by the increased cleavage of PARP and caspase 3, increased expression of 





            Today, taxane-platinum chemotherapeutic drug combinations remain the standard 
of care as first-line regimens for all sub-types of advanced NSCLC with no targetable 
driver genetic mutations. Cisplatin (cis-Pt) alongside paclitaxel (PAC) although highly 
toxic, is the most widely used and most efficacious two-drug combination for the treatment 
of advanced NSCLC [13, 16, 48]. However, due to drug resistance, tumor relapse, and 
metastasis, the response rate has plateaued at 20 - 30% and the survival efficacy is currently 
about 10-14 months [48, 49]. Moreover, despite advancements in molecularly targeted 
drugs and immunotherapies, chemoresistance and metastasis remain almost universal in 
NSCLC [46]. In addition, the currently used chemotherapeutic drugs are highly toxic, 
sometimes causing severe, irreversible and life-threatening toxicities in patients. Thus, the 
systemic treatment of advanced NSCLC remains a major therapeutic challenge, and there 
is a significant unmet clinical need to develop safe and efficacious alternative therapies for 
advanced NSCLC.  
            In the present study, we investigated the efficacy of various combinations of WFA 
and PAC synergistic against the growth and proliferation of human NSCLC cells. WFA, a 
plant-derived steroidal-lactone is the most prominent member of a large group of naturally 
occurring 28-carbon compounds called withanolides. Previously, multiple preclinical 
studies have extensively examined the anticancer effects of WFA on different cancer types 
[22]. In the current study, we demostrate that WFA is highly active against the proliferation 
of the human NSCLC cell lines, H1299 and A549. Mechanistically, at cytotoxic 
concentrations, WFA increased the generation of ROS, an indicator that WFA induces cells 
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to undergo oxidative stress, and subsequently apoptosis. The generation of ROS was 
comfirmed by using a H2O2 as a positive control and was inhibited in the presence of the 
ROS quencher, NAC. Interestingly, whereas we observed that ROS production was related 
to the cytotoxicity of WFA, only thiol containing ROS quenchers such as NAC and DTT 
inhibited the antitumor effects of WFA. Understandably, this phenomenon indicated that 
the generation of ROS was secondary to the cytotoxic antitumor activities of WFA. 
Therefore, although not fully investigated in present study, it appears that the molecular 
mechanism of action of WFA involve thiol binding as one of the more critical steps.  
            To establish the in vitro potency and efficacy, we have demonstrated that WFA as 
a single agent was active against both H1299 and A549 cells. However, since it is highly 
unlikely that NSCLC would be treated with monotherapy, the more attractive approach 
was to investigate the synergistic combination of WFA with standard chemotherapeutic 
drugs [41, 43, 76]. Along these line, we explored the potential for WFA to synergize the 
effects of PAC and/or cis-Pt against the proliferation of human NSCLC cells. This strategy 
was particularly exciting for the case of NSCLC since the clinical efficacy with the current 
treatments seems to have reached a maximum with disappointingly low survival outcomes 
[43]. Based on the data presented, as individual drugs, PAC, a tubulin inhibitor showed the 
greatest potency (lowest IC50) against both H1299 and A549 human NSCLC cell lines. 
These findings are supported by several previously published studies [59, 60] and strongly 
suggest that PAC remains the most important component of the PAC+cis-Pt combination 
in NSCLC treatment. As such, we took PAC to represent the standard of care and then 
demonstrated that its combination with WFA resulted in much greater efficacy than when 
combined with cis-Pt, the standard of care.  
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             Chou et al [71] have developed a robust method for the analysis of the synergism 
for two or more drug combinations using the median-effect equations. Several studies have 
applied this method to investigate the synergistic effects of anticancer drugs against breast 
[77], lung, pancreatic [76] and ovarian [41] cancers. Similarly, we used these median-effect 
equations as described previously to determine whether PAC and WFA were synergistic. 
In our studies, we demonstrated that WFA dramatically increased the efficacy and potency 
of both PAC and cis-Pt in a synergistic manner (CI<1). However, the synergistic effects 
observed with PAC and WFA were much greater than those for PAC and cis-Pt or WFA 
and cis-Pt, respectively. Interestingly, in the synergistic combinations, the observed 
dramatic decreases in the IC50 values were much greater for PAC than were for WFA, 
indicating that the greatest contribution towards synergism was from WFA in either cell 
lines. These observations were strongly supported by the findings from previous studies 
[41, 42] in which WFA has been previously reported to synergize the effects of standard 
chemotherapeutic drugs. Therefore, based on the current findings, we hypothesize that 
using WFA alongside PAC in NSCLC would significantly enhance clinical efficacy while 
dramatically decreasing the potential for toxicity in patients. In the clinic, oncologists 
administer chemotherapeutic drugs following complex dosing schedules to prevent 
overlapping toxicities. Liu et al have shown that the synergism of anticancer drugs can be 
enhanced by altering the sequence, concentration, schedule and duration of drug exposure 
[78-80]. To this effect, we investigated whether the synergism observed between PAC and 
WFA could be increased by altering sequence and schedule of treatment. Our findings 
showed that the synergistic effects of PAC and WFA were not scheduled dependent but we 
demonstrated that preincubation of H1299 and A549 cells with WFA for 2 h dramatically 
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enhanced the antiproliferative efficacy of the combination of PAC and WFA. Thus, it could 
be concluded that WFA had a chemosensitizing effect on PAC against NSCLC cells as has 
been repoted in previous studies conducted with other cancer cell types [22].  
             Chemoresistance and metastasis remain the primary causes of death in advanced 
NSCLC with no clinically effective approved drugs [81]. At the molecular level, intrinsic 
and acquired resistance mechanisms in tumor cells contribute to >80% of treatment failure 
in NSCLC. Furthermore, accumulating evidence from previous studies has shown that the 
development of chemoresistance is simultaneously induced for multiple antitumor agents 
following the treatment with only one agent. For example, studies [16, 70, 75] have shown 
that chronic incubation of NSCLC cells with PAC treatment induces chemoresistance to 
cis-Pt and other chemotherapeutic agents. At the molecular level, PAC induces cellular 
mechanisms such as EMT in NSCLC cells that trigger the development of chemoresistance 
and metastasis. In the present study, we used a previously developed PAC resistant (TR-
A549) cell line that expressed high levels of MDR1 indicating that chemoresistance was 
mediated by increased drug-efflux from cells. Also, we observed high levels of PDL-1 
expression in TR-A549 cells which strongly suggested a link between the simultaneous 
development of drug resistance and immune evasion in NSCLC [82]. Using this TR-A549 
cell line, we demonstrated that WFA was active against both drug-sensitive and drug-
resistant NSCLC tumor cells. Since WFA was active against this MDR-1 overexpressing 
TR-A549 cell line, it appears that WFA is not a substrate for MDR-1 and has the potential 
to inhibit MDR-1 dependent drug resistance in NSCLC. Furthermore, the TR-A549 cells 
displayed decreased E-cadherin expression, a molecular indicator that PAC induced an 
EMT phenotype in NSCLC. In a recent study [83], we have shown that WFA inhibits EMT 
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in NSCLC cells, and we therefore strongly hypothesize that the use of PAC and WFA can 
prevent the emergence of drug resistance and metastasis in NSCLC. Together, these novel 
findings strongly support our rationale for combining PAC with WFA, and further suggest 
that this strategy has an additional benefit of the ability to prevent the emergence or target 
drug resistance and metastasis in NSCLC.  
             In conclusion, we have investigated and demonstrated the therapeutic potential of 
WFA alone and in combination with PAC against human NSCLC cells. Using in vitro 
antiproliferative assays, we have shown that PAC and WFA are highly synergistic against 
H1299 (large cell carcinoma) and A549 (adenocarcinoma) cells. Moreover, the PAC and 
WFA combinations were more efficacious than PAC and cis-Pt or WFA and cis-Pt, 
respectively, against both H1299 and A549 human NSCLC cells. In addition, WFA was 
active against the proliferation of the drug-resistant (TR-A549) cells and decreased the 
expression of MDR-1 in these cells. Together these findings provide a strong rationale for 
further development of the PAC and WFA combination to advance a new therapeutic 





WITHAFERIN A INHIBITS EPITHELIAL TO MESENCHYMAL TRANSITION IN 
NON-SMALL CELL LUNG CANCER CELLS 
INTRODUCTION 
        Lung cancer is the leading cause of cancer-related deaths worldwide [10] and in the 
United States [44]. Non-small cell lung cancer (NSCLC) which accounts for about 85-90% 
of all lung cancer cases has an overall five-year survival rate of 15-17% [84, 85]. Despite 
recent advancements in early detection methods [81, 86], surgical techniques, targeted and 
immunotherapies [87], the overall survival from NSCLC has only minimally improved. 
This poor prognosis is explained in part because about 50-70% of all NSCLC patients are 
diagnosed when the disease is at an advanced stage and are not curable regardless of 
treatment approach [81]. Furthermore, the rate of tumor recurrence among NSCLC patients 
who undergo surgical resection is about 30-70%, most of whom eventually succumb to 
metastasis [15, 45].  
            Tumor cell migration, invasion, and metastasis are the primary causes of treatment 
failure and death among NSCLC patients [84, 88]. Unlike cellular proliferation, the 
therapeutic targeting of metastasis is difficult with no clinically-effective drugs. Metastatic 
processes are complex, and the underlying mechanisms are still poorly understood. because 
they utilize an interplay of cell adhesion, motility, and survival pathways [89].  
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Recently, several clinical and preclinical studies indicate that epithelial-to-mesenchymal 
transition (EMT) plays is a crucial role in the metastatic process of NSCLC cells [90, 91]. 
EMT is a complex but dynamic biochemical process of cellular reprogramming where 
epithelial cells undergo extensive molecular and morphological changes to acquire a 
mesenchymal phenotype. Normally, EMT critical during embryogenesis, angiogenesis and 
wound healing but tumor cells invoke EMT to increase their motility, migratory, and 
invasive capacities [92, 93]. The importance of EMT in metastasis has prompted the 
evaluation of small molecule inhibitors of EMT as potential drugs against metastasis in 
NSCLC [89].  
         Withaferin A (WFA) is a biologically active steroidal-lactone that was first isolated 
from the extracts of the Indian Ayurvedic medicinal plant, Withania somnifera [24]. 
Previous studies have demonstrated multiple pharmacological effects of WFA including 
antitumor, anti-inflammatory, pro-apoptotic, immunomodulatory, hepatoprotective, 
anabolic, antiangiogenic, and anti-fibrotic activities. Despite these multiple effects, WFA 
has attracted significant preclinical testing mainly for its antitumor activities [22]. Indeed, 
WFA has been shown to be cytotoxic against lung [40, 62-64], cervical [66], prostate [39, 
94], breast [31, 35, 37], ovarian [41-43], colon [95], B-cell lymphoma [68], and pancreatic 
[76] cancers in the preclinical setting. More importantly, in addition to cytotoxicity, WFA 
displays remarkable anti-invasive and anti-metastatic activities [22, 31, 96]. Although the 
molecular mechanisms underlying the activity of WFA are not fully understood, its anti-
metastatic effects have been attributed in part to its inhibition of EMT in tumor cells.  
         Previously, anti-EMT properties of WFA have been demonstrated on breast, ovarian, 
and mammalian epithelial cells [22]. In the present study, we examined the effects of WFA 
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on migration, invasion, and EMT induction in A549 and H1299 cells. Here, we show that 
the cytokines TGF1 and TNF cooperate to induce EMT, increase migration and invasion 
of these tumor cells. Importantly,  we demonstrated that sub-cytotoxic doses of WFA 
suppressed TGF/TNF-induced EMT, cell adhesion, migration, invasion, and motility. 
Mechanistically, WFA inhibited TGF1-dependent Smad2/3-signaling and TNF-
dependent NFκB signaling. Together, this data provides additional evidence on role WFA 
in regulating EMT in tumor cells and further demonstrates the therapeutic potential of 





MATERIALS AND METHODS 
Reagents, chemicals, and supplies. 
WFA (>96% pure) was generously provided as a gift sample by 3P Biotechnologies Inc., 
(Louisville, KY, USA). A stock solution of WFA (5 mM) was prepared in dimethyl 
sulfoxide (DMSO) and stored in aliquots at -20°C until use. MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide) was purchased from Alfa Aesar (Ward Hill, MA, 
USA).  RIPA cell lysis buffer, BCA protein assay kit, PVDF membranes, phosphate-
buffered- saline (PBS), ECL chemiluminescence reagent, and Bolt 4-12% Bis-Tris 
phosphate gels were purchased from ThermoFisher (Rockford, IL, USA). Dulbecco's 
modified Eagle’s medium (DMEM), penicillin and streptomycin were purchased from Life 
Technologies (Gibco, Grand Islands, NY, USA). Fetal bovine serum (FBS) was purchased 
from VWR, Seradigm Life science (Radnor, PA, USA). The human recombinant TGFβ-1 
(#8915) and TNFα (#8902) were purchased from Cell Signaling Technology (Danvers, 
MA, USA) and prepared as 50 µg/mL stock solutions in sterile 20 mM citrate, pH 3.0 and 
sterile PBS, respectively. The stock solution was stored in aliquots at -80°C and diluted in 
serum-free DMEM media before use. 
Antibodies.  
Primary antibodies against Smad2/3, phospho-Smad2/3, Smad 2, Smad3, phospho-Smad2, 
phospho-Smad3, Smad4, Smad7, Snail, Slug, E-cadherin, ZEB1, N-cadherin, Vimentin, 
NFκB, pNFκB, IκB, phospho-IκB, IKKα, IKKβ, phospho-IKKα/β, and were purchased 
from Cell Signaling Technology (Danvers, MA). The primary antibodies against β-actin 
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were purchased from Sigma Chemical Co. (St. Louis, MO). A detailed list of all antibodies 
used is presented in Supplementary Table 1.  
Cell culture conditions. 
The human NSCLC cell lines, A549, and H1299 were maintained in DMEM media 
supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% antibiotics (100 U/mL 
penicillin and 100 µg/mL streptomycin), at 37°C with 5% CO2 in a humidified incubator. 
Culture media was replaced every 48h and the cells were passaged at 80% confluence, 
for less than 20 cycles. 
Cell viability assay.  
Cell viability was determined by MTT assay as described previously. Briefly, cells were 
seeded in 96-well plates (3 x 103 cells/well) and preincubated for 24 h before treatments. 
DMEM was replaced with fresh media containing various concentrations [0-5 µM] of 
WFA and incubated for an additional 24, 48, and 72 h. The cells were then incubated with 
the 0.5 mg/mL MTT reagent for 3 h and formazan crystals formed were solubilized using 
200 µL of DMSO. The absorbance of the resulting solution was measured at 570 nm. Data 
were expressed as mean  SD of four or more separate experiments.  
Cell adhesion assay.  
Cells were serum starved for 12 h and then incubated with WFA in the presence or absence 
of TGFβ1 or TNFα in serum-free media for 1 h. The cells were then seeded in Matrigel (50 
μg/mL) pre-coated 96-well plates (5 x104 cells/ well) and incubated for 2 h to allow 
attachment. Non-adherent cells were washed away using pre-warmed sterile PBS, and then 
fresh DMEM media (10% FBS) was added to each well. Cultures were incubated for an 
additional 4 h, and then cell viability was measured using MTT assay.  
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Colony formation assay. 
Cells were incubated with or without WFA for 24 h, trypsinized and then seeded in 6-
well plates at 200 cells/well density. Fresh DMEM media was added and changed every 
48 h for a total of 7 d. The colonies formed were fixed using methanol/acetic acid 
solution (3:1), and stained with 0.2% crystal violet. The number of colonies formed was 
recorded using a high-resolution digital camera and counted using a microscope in five 
random fields.  
Wound healing assay. 
The wound-healing assay was performed using the 2-well inserts from ibidi® (Munich, 
Germany). Briefly, cells (1 x104 cells/well) were seeded into the 2-well inserts and 
incubated for 24 h to allow cell attachment. The cell-free gaps (wounds) were created by 
removing the culture inserts. Floating cells and cellular debris were washed off using sterile 
PBS, and media was replaced with fresh media containing WFA in the presence or absence 
of TGFβ1 and TNFα. The distance migrated by cells in each cell-free gap was monitored 
by light microscopy at 0, 12, and 24 h. At each time point, 3 random microphotographs of 
the wound area were taken. The percent migration was quantified using Wimasis Image 
Analysis software (WimScratch, Cordoba, Spain). 
Transwell migration and invasion assays. 
Migration and invasion assays were performed using uncoated and Matrigel-coated 8 µm 
pore transwell chambers (BD Bioscience, San Jose, CA), respectively. Cells (4 x 104 
cells/well) were suspended in serum-free DMEM media and seeded into the upper 
compartments of transwells. DMEM media containing 10% FBS was added to the lower 
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chamber as a chemoattractant to cause cell migration from the upper chamber to the lower 
chamber of the transwells. Cell migration was allowed to occur for 24 h, and the migrated 
cells were fixed using 4% paraformaldehyde solution. Cells were permeabilized using 
100% methanol and then stained using 0.2% toluidine blue. Migrated cells in five random 
fields were examined using a microscope and microphotographs taken using a high-
resolution digital camera.  
Western blot analysis.  
Following incubation with indicated treatments, cells were harvested by trypsinization and 
washed twice with ice-cold PBS. Whole-cell protein lysates were prepared by suspending 
cell pellets in RIPA cell lysis buffer at 4C. Protein concentration for the cellular lysate 
was determined by BCA method and protein samples (20 µg) were resolved by SDS-PAGE 
and then transferred to PVDF membranes. The expression of specific proteins was 
determined by probing the PVDF membranes with specific primary monoclonal 
antibodies, followed by the respective HRP-conjugated secondary antibodies. The levels 
of each protein were determined by visualizing protein bands on blots using ECL detection 
reagents (Thermo Scientific, Rockford, IL). The relative density of each blot was quantified 
using the ImageJ software (NIH, Bethesda, MD). β-actin (Sigma-Aldrich, St. Louis, MO) 
was used as protein loading controls. 
Electrophoretic Mobility Shift Assay (EMSA). 
To determine the effect of WFA on the binding of NFκB to nucleic acids, the 
electrophoretic mobility shift assay (EMSA) was performed. Briefly, cells were incubated 
with or without WFA for 24 h, and then was NFκB stimulated using 5 ng/mL TNFα for 30 
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min. Cytosolic and nuclear cell extracts were prepared using standard protocols. A total of 
30 µg nuclear protein was incubated with 32P end-labeled double-stranded NFκB, and the 
DNA–protein complex formed were separated from free oligonucleotide on 6% native 
polyacrylamide gels. The radioactive bands were visualized by a Packard InstantImager. 
Immunofluorescence staining.  
Cells were seeded in 8-well chamber slides and cultured up to 60-70% confluency. After 
24 h serum starvation, cells were incubated with TGF1 or TNF in the presence or 
absence of WFA for 24 h. Then, cells were fixed using 4% paraformaldehyde and 
permeabilized using 0.25% Triton X-100 in PBS. The fixed cells were blocked using 1% 
BSA for 1 h at 23°C and then probed with specific primary antibodies at 4°C overnight. 
The primary antibodies were then probed with fluorescent-tagged secondary monoclonal 
antibodies diluted in 1% BSA in PBS for 2 h at 23°C. F-actin was stained using green or 
red fluorescent phalloidin while the nuclei were stained blue using DAPI. 
qRT-PCR analysis. 
Total RNA was extracted from cells using Trizol reagent (Invitrogen, Carlsbad, CA) as 
per the manufacturer’s instructions. The relative expression of E-cadherin, vimentin, 
Snail, and fibronectin mRNA levels were determined by qRT-PCR and normalized to 
the expression of GAPDH. qRT-PCR was performed using Power SYBR Green RNA to 
CT 1-Step Kit. The primers used in the qRT-PCR assay are listed in table 1 in the 
supplementary information. Relative mRNA levels were determined by calculating the 




Statistical analysis.  
Statistical analysis was performed using Graph Pad Prism 7.0 software. Data were 
presented as means ± SD of at least 3 separate experiments. First, One-way analysis of 
variance (ANOVA) was used to determine variations among experimental and control 
groups. Comparisons of individual experimental and control group means were done using 





WFA inhibits the growth and proliferation of A549 and H1299 cells.  
            First, we determined the cytotoxic effects of WFA against the two human NSCLC 
cell lines H1299 and A549, which are known to be highly and moderately metastatic, 
respectively. Incubation of cells with WFA caused dose- and time-dependent cytotoxicity 
to both A549 and H1299 cells. Phase-contrast images (Fig. 3.1b) were obtained after 48 h 
of cell culture in the presence of WFA. The images revealed significant dose-dependent 
changes in cellular morphology of both A549 and H1299 cells, that were indicative of 
decreased cell viability and/or increased cell death. To quantitatively determine the 
cytotoxic effects of WFA on A549 and H1299 cells, we used the MTT assay to measure 
cell viability. By considering the vehicle-treated cells as 100% viable, our data (Fig. 3.1c) 
shows that WFA dose-dependently decreased the viability of both A549 and H1299 cells. 
The anti-proliferative effects of WFA on NSCLC cells were both time- and concentration-
dependent (Fig. 3.1d-e). 
            Next, to validate the MTT data, we assessed the effects of WFA on the replicative 
ability of A549 and H1299 cells by conducting the colony formation assay. Representative 
images (Fig. 3.1f) of A549 and H1299 colonies stained using 0.5% crystal violet in 
methanol. In support of our MTT assay data, WFA significantly inhibited the ability of 
cells to form colonies. Together, this data demonstrates the remarkable cytotoxic effects 
of WFA against A549 and H1299 human NSCLC cells in vitro. Overall, we found the 







Fig 3.1. WFA suppressed the growth and proliferation of A549 and H1299 cells. (a) 
Chemical structure of WFA. (b) Phase-contrast images (4X magnification) showing the 
cellular morphology following incubation with WFA for 48 h. (c) Dose-dependent 
antiproliferative activity of WFA against A549 and H1299 cells after 72 h incubation. 
Time- and concentration-dependent inhibitory effects of WFA on the growth and 
proliferation of A549 (d) and (e) H1299 cells. (f) Representative images of colony 
formation assay depicting a dose-dependent inhibitory effect of WFA on A549 and H1299 
cells. Cell viability was measured using MTT assay while the number of colonies formed 
were counted using a microscope and data are presented as mean ± SD of 3 technical 
replicates.  *p<0.05,   **p<0.01.  
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WFA inhibits cell adhesion, migration, and invasion of A549 and H1299 cells 
           Increased migratory and invasive behaviors of tumor cells are known to be 
indicative of higher metastatic potential in NSCLC tumors. Therefore, to test whether 
WFA inhibited the metastatic potential of A549 and H1299 cells, we conducted the cell 
adhesion, migration, and invasion assays. We used the cell adhesion assay to determine 
the potential of A549 and H1299 to attach to an extracellular matrix in the presence of 
WFA. The vehicle-treated cells (Fig. 3.2a) were considered to have 100% adhesion to 
Matrigel, while WFA treated cells displayed dose-dependent in cell adhesion for both 
A549 and H1299 cells. Next, to examine the effects of WFA on cell motility, we 
performed the wound healing assay for both A549 and H1299 cells. We observed (Fig. 
3.2b) that 0.5 µM WFA significantly suppressed cell motility of both A549 and H1299 
cells. In untreated (vehicle-treated) cells, >95% of the wound areas were covered by cells 
indicating higher cell motility. However, in the presence of WFA, we observed only 20-
40% motility of these cells (*p<0.05).     
            Furthermore, we also determined the effect of WFA on transwell migration and 
invasion using 8 µm-pore transwell chambers coated with or without Matrigel. The number 
of migrated cells were counted in five random fields under a microscope and presented as 
mean ± SD. Representative microphotographs of migrated and invaded cells show that 








Figure 3.2. WFA inhibited cell adhesion, motility, migration, and invasion of A549 and 
H1299 cells. (a) Cell adhesion assay depicting the dose-dependent inhibition of the 
adhesion of A549 and H1299 cells. (b) Wound healing assay showing the inhibitory effect 
of WFA on the motility of A549 and H1299 cells. (c) Representative images showing the 
effect of WFA on transwell migration and invasion of A549 and H1299 cells following 
incubation with WFA. Data are mean ± SD, *p<0.05.  
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WFA inhibited experimental EMT induction in A549 and H1299 cells. 
           The loss of the epithelial marker E-cadherin and an increase in the expression of 
N-cadherin (also known as the cadherin switch) is the hallmark of EMT induction in 
tumor cells. Previously, TGFβ1 and TNFα either individually or in combination have 
been used to induce experimental EMT in various tumor cell types including NSCLC. 
In the present study, we assessed whether WFA could inhibit experimentally induced 
EMT in A549 and H1299 cells. First, we induced EMT in A549 and H1299 cells by 
culturing cells in serum-free media containing TGF1 (5 ng/mL) and TNF (25 ng/mL) 
alone or in combination. Data presented (Fig. 3.3a) shows the western blot analysis of 
whole-cell lysates prepared from A549 and H1299 cells following EMT induction. In 
the vehicle-treated cells, the highly invasive H1299 cells did not express E-cadherin but 
A549 cells expressed significant levels of E-cadherin. However, incubation of A549 
cells with TGFβ1 and TNFα either alone or in combination resulted in a significant 
decrease in the expression of E-cadherin in A549 cells while upregulating N-cadherin. 
This finding indicated that culturing A549 cells in the presence of these cytokines 
resulted in EMT induction. Using qRT-PCR analysis (Fig. 3.3b), it was found that the 
repression of E-Cadherin expression was associated with decreased levels of mRNA in 
A549 cells. On the other hand, the expression levels of the EMT-related proteins such 
as vimentin, Snail, fibronectin, and claudin-1 were all significantly increased after 
incubation with the cytokines. Interestingly, the expression of Snail, a known EMT 
transcription factor was significantly increased by TGFβ1 alone or in the combination 
of TGFβ1 and TNFα but not TNFα. Also, only TGFβ1 significantly increased the 
expression of vimentin as indicated by western blot (Fig. 3.3a) and qRT-PCR (Fig.3.3b).  
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Fig 3.3. WFA inhibited experimental EMT induction in A549 and H1299 cells. Cells 
were left untreated or pretreated with 0.5 µM WFA for 12 h and then stimulated with 
TGFβ1 or TNFα alone and in combination in serum free media. EMT induction was 
assessed by western blot analysis, qRT-PCR, and immunofluorescence staining. (a) 
Western blot analysis depicting the expression levels the epithelial marker E-cadherin, and 
the EMT-related proteins N-cadherin, Snail, vimentin, and fibronectin (b) qRT-PCR 
depicting the relative mRNA expression. Fold change was calculated using the ΔΔCт 
method and GAPDH was used as normalizing gene. (c) Phase-contrast images (4x 
magnification) and confocal images showing changes in cellular morphology and the 
expression of E-cadherin and vimentin in A549 cells following incubation with a 
combination of TGFβ1 and TNFα in the presence or absence of 0.5 µM WFA. (*p<0.05 
vs. untreated).   
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When cells were pre-incubated with 0.5 µM WFA prior to EMT induction, the observed 
repression of E-cadherin or the upregulation of vimentin, Snail, fibronectin, and claudin-
1 were inhibited. This inhibitory effect of WFA was confirmed using both western blot 
analysis and qRT-PCR analysis. To further validate these data, we performed 
immunofluorescence staining to determine the expression of E-cadherin and vimentin 
in A549 cells following EMT induction. Phase contrast and confocal images (Fig 3.3c) 
show the morphological changes, downregulation of E-cadherin, and the upregulation 
of vimentin as indicators of EMT induction in A549 cells. There was evidence of loss 
of cell to cell contact, and the cells became more elongated. However, in support of data 
obtained by western blot and qRT-PCR analysis, WFA significantly inhibited EMT 
induction in A549 cells. Further, we assessed the effects of WFA motility of both A549 
and H1299 cells in the presence of TGF1 and TNF. As indicated (Fig. 3.4), TGFβ1 







Fig 3.4. WFA suppressed TGFβ1/TNFα-induced motility of A549 and H1299 cells. 
Wound healing assay was used to measure the motility of the cells in the presence 0.5 µM 
WFA and a combination of TGFβ1 (5 ng/mL) or TNFα (25 ng/mL). The figure shows that 
TGFβ1/TNFα significantly enhanced the motility of A549 (a), and H1299 (b) cells. Data 
are presented as percent migration (mean ± SD) by considering wound area at time 0 h as 




WFA inhibited TGF1-dependent Smad2/3 signaling in A549 and H1299 cells 
            TGFβ1-induced EMT in tumor cells has been shown to occur mainly through the 
activation of Smad-dependent signaling pathways. Therefore, to assess whether WFA 
affected TGFβ-induced Smad2/3 activation, cells were incubated with WFA at indicated 
concentrations and then stimulated with TGFβ1 (5ng/mL). The phosphorylation of 
Smad2/3 was assessed by immunofluorescence staining and western blot analysis. 
Confocal images (40x magnification) of A549 cells (Fig. 3.5a) shows probed for p-
Smad2/3 (green), F-actin (red) and nuclei (blue). These images show that TGF1 
increased the levels of p-Smad2/3 and its nuclear localization when compared to vehicle-
treated cells. However, pre-incubation of cells with WFA prior to TGFβ1stimulation, 
the phosphorylation and nuclear translocation of Smad2/3 was inhibited. 
           To validate the confocal data, we performed western blot analysis on whole cell, 
nuclear, and cytoplasmic lysates prepared from A549 and H1299 cells. As shown in 
(Fig.3.5b), we observed that WFA dose-dependently suppressed Smad2 and Smad3 
phosphorylation and thus prevented their nuclear translocation. Moreover, it appears 
that WFA also decreased the levels of total Smad3 in a dose-dependent manner. Overall, 
the data presented here show that WFA inhibited TGFβ1-induced EMT at least in part 





Fig 3.5. WFA inhibited TGFβ1-dependent activation of Smad2/3 in A549 and H1299 
cells. (a) Confocal images of A549 NSCLC cells depicting the inhibitory effect of WFA 
(1.0 µM) on TGFβ1 (5 ng/mL)-induced Smad2/3 phosphorylation in A549 cells. (b) 
Western blot analysis of whole cell lysates depicting the dose-dependent inhibitory effect 
of WFA on the Smad2/3 signaling pathway (c) Western blot analysis of cytosolic and 
nuclear fractions from A549 cells showed decreased Smad2/3 phosphorylation and nuclear 
translocation in the presence of WFA. GAPDH was used the total protein loading control.  
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WFA inhibited TNF-induced NFB signaling in A549 and H1299 cells. 
           TNF stimulates aberrant NF-κB signaling pathways in tumor cells to regulate 
motility, migration, invasion, and chemo-resistance [97]. In the present study, we 
investigated whether WFA inhibited TNF-induced activation of NFB in H1299 and 
A549 cells. As shown in Figure 6, TNF stimulated the NF-B signaling pathway by 
inducing the phosphorylation and nuclear translocation of NF-B (P65). As assessed by 
immunofluorescence staining (Fig. 3.6a), cells stimulated with TNF had higher levels 
of p-NF-B than vehicle-treated controls. However, pre-incubation of cells with WFA 
significantly decreased the phosphorylation of NFB. Western blot analysis (Fig. 3.6b-
c) of the whole-cell and cytosolic lysates indicates that TNF alone increased the 
phosphorylation of IBα (p-IBα) and NFB (p-NF-B). The phosphorylation of IκB 
resulted in increased degradation of IB and the nuclear translocation of NF-κB (P65). 
However, WFA suppressed the TNF-dependent phosphorylation of NF-B (P65) and 
IBα, the degradation of IBα and nuclear translocation of NF-κB (P65). Interestingly, 
the total levels of NF-κB (P65) were not significantly affected by WFA indicating that 
WFA inhibited NFκB signaling by regulation phosphorylation. By measuring the levels 
of total and phosphorylated IKKα/β, we found that WFA inhibited NF-κB(P65) by 
regulating the activity of IKKα/β. Furthermore, we also investigated the effect of WFA 
on the transcriptional activity of NFκB (P65) using the electrophoretic mobility shift 
assay (EMSA). Our data (Fig. 3.6e) shows WFA decreased the binding of NFκB (p65) 
on to DNA in both A549 and H1299 cells. Overall, we demonstrate that WFA 
remarkably inhibited TNF-induced degradation of IB resulting in inhibition of the 

























Fig 3.6. Inhibition of TNFα-induced NFκB activation in human NSCLC cells. (a) 
Confocal images (40x magnification) showing the levels of p-NF-κB. (b) Western blot 
analysis depicting levels of p-NFκB, total NF-kB, p-IκB, and total IκB in whole cell lysates 
following stimulation with TNFα (25 ng/mL (c) Western blot analysis of nuclear and 
cytosolic cell extracts depicting levels of NFκB, p-NFκB, IκBα, and p-IκBα following 




            Despite the recent advances in the treatment of NSCLC such as targeted therapies 
and immunotherapies, invasion and metastasis remain a major therapeutic challenge in 
NSCLC [81]. Recently, it has become clear that EMT plays a crucial role in the metastasis 
of NSCLC tumors and therefore has become an attractive drug target [90]. It has been 
shown that EMT induction causes tumor cells to become more migratory, invasive, and 
metastatic [92].  Additionally, EMT stimulates tumor cells to acquire stem cell-like 
properties and increases resistance to standard chemotherapeutic drugs [98]. Therefore, the 
importance of EMT during metastasis and in drug resistance of tumor cells has prompted 
the search for compounds that inhibit EMT in tumor cells as potential drugs for metastatic 
NSCLC [99]. Based on this hypothesis, we and others [31, 43, 96] have examined the 
effects of WFA on experimentally induced EMT to demonstrate its potential anti-
metastatic properties. 
            WFA is a member of the withanolides, a large group of naturally occurring 
28carbon-containing compounds [19]. The basic chemical structure of withanolides is 
composed of a steroidal framework attached to a lactone ring, and are also referred to as 
‘steroidal-lactones’ [20]. In WFA (Figure 1A), there are five functional groups including; 
an unsaturated ketone ring, 2 hydroxyl groups, an epoxide ring, a 6-carbon lactone ring, 
and an unsaturated carbonyl group [27, 28]. It has been shown that these five functional 
groups enable WFA to interact with several molecular targets and account for the diverse 
biological activities of WFA including its anti-cancer properties [22]. Multiple lines of 
experimental evidence from in vitro and in vivo studies show that WFA is a highly 
efficacious anti-tumor molecule that displays both cytotoxic activities against multiple 
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cancer cells [37, 64, 100]. Recently, the effects of WFA on tumor cell migration, invasion, 
and metastasis [22]have gained a lot of attention and have stimulated interest in 
investigating the anti-metastatic properties of WFA. Importantly, unlike common cytotoxic 
chemotherapeutic drugs that have been shown to induce EMT [101], WFA, on the other 
hand, suppresses EMT [31, 43, 96, 102] and therefore has the capability to prevent 
metastasis and drug resistance in multiple cancers.      
            Earlier studies have shown that sub-cytotoxic doses inhibit EMT induction in the 
breast, ovarian, and mammalian epithelial cells [96, 103]. In fact, detailed molecular 
evidence showed that WFA binds to and causes the degradation of the EMT-related 
intermediate filament protein, vimentin [31]. Similarly, our study highlights the role of 
WFA in regulating EMT and metastasis in tumor cells. Initially, we determined the 
cytotoxicity of WFA on anchorage-dependent growth and proliferation of A549 and H1299 
cells. As reported elsewhere [64], our findings show remarkable cytotoxicity of WFA on 
the anchorage-dependent proliferation of NSCLC cells. Notably, the highly invasive 
H1299 cells were more sensitive to WFA than the moderately invasive A549 cells. This 
finding suggests and strengthens the hypothesis that WFA is likely more potent against the 
highly metastatic tumors which are incidentally found in the majority of NSCLC patients.  
             During the EMT process, tumor cells lose cell to cell contacts, become more 
invasive and resistant to cytotoxic drugs [104]. At the molecular level, it is reported that 
the loss of the epithelial marker E-cadherin coupled with an increase in mesenchymal 
markers such as vimentin and N-cadherin are the hallmarks of EMT [90]. Furthermore, 
EMT pathways are regulated by various extracellular signals including cytokines in the 
tumor microenvironment such as TGF1 and TNFα [104, 105]. Experimentally, EMT 
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induction in tumor cells has been modeled by culturing cells in serum-free media 
containing TGFβ1 and/or TNFα [92]. Using this model, we successfully induced EMT in 
A549 and H1299 cells using TGF1 and TNF. In agreement with previous studies [106], 
our findings data shows synergistic cooperation between TGF1 and TNF on E-cadherin 
repression. More importantly, pre-incubation of cells with WFA prior to EMT induction 
prevented the loss of E-cadherin or the upregulation of N-cadherin. Together with previous 
data [31, 96, 107], our study demonstrates that WFA is a powerful suppressor of EMT 
induction and further highlights the anti-metastatic effects of WFA. 
            The molecular mechanisms underlying EMT are complex but the transcription 
factor Snail has been shown to be a key regulator of EMT induction in NSCLC cells [105]. 
Specifically, Snail binds to DNA and causes the repression of E-cadherin expression while 
upregulating EMT-related proteins such as vimentin, N-cadherin, and fibronectin [92, 98, 
105]. Snail expression and function are regulated by extracellular signals such as TGFβ1 
[90, 92] and TNFα [106] via Smad- and NF-κB-dependent signaling pathways, 
respectively. Moreover, simultaneous activation of these two pathways synergistically 
increases the expression Snail in A549 cells [106, 108, 109]. In agreement with this 
observation, we demonstrated that a combination of TGF1 and TNF synergistically 
increased the expression of Snail. Because Snail represses E-cadherin expression, this 
finding explains the observed synergistic interaction between TGF1 and TNF on EMT 
induction as indicated by the enhanced loss of E-cadherin and upregulation of N-cadherin. 
However, WFA pre-incubation abrogated the cytokine-dependent increase in Snail 
expression, and further prevented the loss of E-cadherin thus preventing EMT induction. 
Overall, these findings suggest that the observed inhibition of EMT induction by WFA 
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occurs at least in part due to the regulation of Snail expression by inhibiting Smad and/or 
NF-B signaling pathways. 
            To further understand the potential mechanisms underlying the inhibitory effects of 
WFA on TGF1/TNF-dependent EMT induction, we explored Smad and NF-κB 
signaling pathways. Smad2 and Smad3 belong to a family of transcription factors that exist 
as a Smad2/3 dimer in the cytoplasm in the inactive (dephosphorylated) form. However, 
following TGFβ1 stimulation, these are phosphorylation, then bind to another cytosolic 
protein called Smad4 and translocate to the nucleus where they stimulate the expression of 
Snail [105]. Therefore, to determine whether WFA inhibits the activation of Smad 
signaling, we measured the levels of total and phosphorylated Smad2, Smad3, and Smad4 
in whole-cell, cytoplasm, and nucleus. Although WFA has already been shown to inhibit 
Smad2/3 phosphorylation [107], our study provides additional evidence on the multiple 
effects of WFA on Smad signaling. WFA inhibited the phosphorylation of both Smad2 and 
Smad3, and thus prevented their nuclear translocation. Additionally, it appears that WFA 
also targeted Smad3 and caused its degradation.  
           Several published studies have shown that WFA is a potent anti-inflammatory 
activity and has been extensively studied for its effects NF-κB signaling mechanisms [22, 
100, 110, 111]. In tumor cells, it is known that TNF activates the NF-κB signaling to 
stimulate EMT induction, cell survival, proliferation, migration, and chemo-resistance [97, 
109]. Mechanistically, the activation of NFB involves two major events; (1) IKK/ 
dependent phosphorylation and subsequent degradation of IκBα, the inhibitor of NF-κB 
(P65), and (2) the phosphorylation and nuclear translocation of NF-B (P65). Data from 
previous studies [110] conducted on fibrosarcoma and human embryonic kidneys cells 
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indicated that WFA regulated NF-κB signaling by inhibiting the kinase activity of IKKα/β. 
This resulted in decreased phosphorylation and degradation of IB, the phosphorylation 
and nuclear translocation of NF-B (P65). Because TNF is known to induce EMT via the 
NF-B pathway, we also assessed the effect of WFA on NF-B signaling. In agreement 
with previous findings, we also observed dose-dependent inhibition of TNF-dependent 
activation of NF-κB signaling in both A549 and H1299 cells. The phosphorylation and 
degradation of IB was inhibited and was concomitant with decreased NF-κB 
phosphorylation, nuclear translocation, and binding to DNA. These findings provide 
additional supporting evidence of the inhibitory effect of WFA on NFκB signaling via 
interference with IKK/β kinase activity. 
           In conclusion, using a combination of TGF1 and TNF to experimentally induce 
EMT, our study demonstrates the inhibitory of WFA on EMT induction in A549 and 
H1299 NSCLC tumor cells. Although detailed molecular mechanisms have not been 
elucidated, our data provides a basis for the conclusion that WFA regulates EMT via the 
regulation of Smad and NFκB signaling pathways. Together, the findings presented here 
and in previous studies suggest that WFA is a promising antitumor agent that has 
therapeutic potential in the treatment of metastatic NSCLC cancer. Additionally, our 
observation that WFA was more potent against the highly invasive H1299 cells than the 






REPEATED DOSING TOXICITY AND PHARMACOKINETICS OF WITHAFERIN A 
IN SPRAGUE DAWLEY (SD) RATS 
INTRODUCTION 
           Pharmacokinetics defines the processes of absorption, distribution, metabolism, 
and the excretion of drugs in the body [112]. Currently, systemic chemotherapy using 
cytotoxic agents remains the mainstay in the treatment of advanced NSCLC without 
targetable mutations [9]. In NSCLC, multiple high doses of cytotoxic drugs are often 
used to achieve the desired therapeutic response [16]. Many of the drugs used have a very 
narrow therapeutic window and require precise therapeutic dose monitoring to minimize 
the risks for toxicity. Traditionally, the dosing of NSCLC patients with various standard 
chemotherapeutic agents is based on the assumption of a linear relationship between body 
surface area (BSA) and clearance (CL) or volume of distribution (Vd) [113]. However, 
remultiple clinical trials [112, 114] have shown that this is not true and that most 
anticancer agents show interindividual pharmacokinetic variabilities. For example, 
systemic exposure (AUC) after standard doses of paclitaxel varies by up to 10-fold 
between patients [112]. Moreover, NSCLC patient populations are often very diverse and 
complex, which creates the need for explicit drug dosing recommendations.  
 80 
 
             The high variability of the pharmacokinetic properties of cytotoxic anticancer 
drugs in patient populations make it very difficult for oncologists to predict individual 
clinical responses in patients [112]. Moreover, with variable pharmacokinetics comes 
an increased risk of both toxicity and sub-therapeutic dosing, leading to compromised 
clinical efficacy [114]. On the other hand, if a drug has well-characterized 
pharmacokinetic properties, it is possible to decrease interindividual pharmacokinetic 
differences, minimize toxicity and enhance clinical efficacy by tailoring doses to the 
individual patient (the so called individualized dosing) [12, 48]. Therefore, to enhance 
clinical efficacy, it is important to characterize the toxicity and pharmacokinetics of new 
anticancer agents early enough in the drug discovery process to provide a framework for 
designing safe and efficacious dosing schedules. 
   Withanolides are a novel class of bioactive compounds that have shown multiple 
pharmacological activities [115]. Withaferin A (WFA) is the most prominent member of 
this class of compounds and has emerged as a potential therapeutic agent for cancer [22, 
24]. Chemically, WFA is a plant-derived steroidal-lactone that was first isolated from the 
alcoholic extracts of the Ayurvedic medicinal plant Withania somnifera [23, 24, 26]. In 
literature, there is a growing body of in vitro and in vivo preclinical data to demonstrable 
the efficacy of WFA against NSCLC [62, 83],  breast [31, 35], cervical [66], prostate [39, 
94], pancreatic [67], renal [116], B-cell lymphoma [68] and ovarian cancers [43]. 
Mechanistically, it has been shown that WFA targets heat shock proteins [117], vimentin 
[31], NFkB [83], IKKβ-kinase [118], STAT3 [22], Blc2, cyclins, EGFR, and PAR-4 [30, 
94]. Together, these varied molecular targets allow WFA to disrupt multiple cellular 
processes such as proliferation, migration, invasion, and metastasis that are critical in the 
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tumorigenesis of NSCLC cells [22]. Unfortunately, despite its demonstrable antitumor 
efficacy in multiple models, WFA is currently stuck at the preclinical testing stage mainly 
due to the lack of toxicity and pharmacokinetics data. There is very limited reliable data on 
important disposition parameters of WFA such as; metabolic stability, plasma protein 
binding, erythrocyte partitioning, excretion properties, and clearance.  
   In the present study, the objectives were to; (1) determine the potential repeated 
dose toxicity, and (2) determine the preclinical pharmacokinetic properties of WFA. 
Briefly, the sub-chronic toxicity of WFA was assessed for three doses (4, 8, 12 mg/kg) of 
WFA in male SD rats following 28-days of repeated oral dosing. The toxic endpoints 
consisted of an evaluation of changes in total body weight gain, food intake, hematological 
and biochemical parameters. On this regard, our data indicate that up to 12 mg/kg of WFA 
was safe and well-tolerated in male SD rats after oral administration. No significant 
changes in total body weight, body weight gain, hematological and biochemical parameters 
were observed. To study the pharmacokinetics of WFA, we first developed a highly 
sensitive analytical method for the quantification of WFA in plasma and tissues. In this 
method, we used HPLC as the chromatographic separation technique coupled to MS/MS 
for detection and quantitation. This analytical method was successfully developed and 
applied to determine the pharmacokinetic properties of WFA after administration of a 
single bolus (i.v.) dose (10mg/kg) in male SD rats. In agreement with previous studies[31], 
WFA displayed linear pharmacokinetics, with very rapid distribution and elimination from 
plasma, and the concentrations fell below the detection limit within 2 h. Further, WFA 





MATERIALS AND METHODS 
Chemicals and reagents 
         Withaferin A (Mol. Wt 470.61, purity > 95% HPLC) was kindly provided by 3P 
Biotechnologies (Louisville, KY, USA). Dimethyl sulfoxide (DMSO, Cat #13390) was 
purchased from Electron Microscopy Sciences (Hatfield, PA, USA). Pooled SD rat liver 
microsomes were purchased from ThermoFisher (Kansas City, KS). Prednisolone 
analytical standard (Mol. Wt. 360.44, Cat#46656) was purchased from Sigma (Sigma–
Aldrich, St Louis, MO, United States). In addition, acetonitrile, methanol, and ultrapure 
HPLC-grade water were purchased from Sigma Aldrich (St. Louis, MO, USA). 
Animals 
Male SAS Sprague Dawley (SD) rats (150-200 g) were purchased from Charles River 
Laboratories. These rats were housed individually or as a maximum of 3 rats/cage in a 
temperature-controlled room (25 °C) with a 12-h light/dark cycle. The rats were allowed 
access to purified AIN-93M diet and water ad libitum The research protocols involving the 
use of animals were approved in advance by the Institutional Animal Care and Use 
Committee (IACUC#17041).  
Sub-chronic toxicity of WFA in male SAS SD rats 
            In this study, a total of 20 male SAS SD rats were used to evaluate the potential 
toxicity of WFA following repeated oral dosing. Prior to the initiation of treatments, the 
rats were allowed a minimum of 7-days acclimation period and then randomly divided into 
4 experimental groups (n=5/group). To the first group, we administered a drug-free vehicle 
(0.1 M β-hydroxypropyl cyclodextrin) in an equivalent volume with drug-treated rats. In 
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the remaining 3 groups, rats were administered with 3 escalating doses of WFA (4, 8, 12 
mg/kg). For the vehicle and all experimental groups, the rats were orally administered with 
treatments three times per week for a total of four weeks (28-days). To assess the potential 
toxicity of the treatments, several toxic endpoints were determined. Firstly, we observed 
the rats daily for clinical signs of toxicity such as overall activity and isolation, breathing 
rate, fur coat, eye color, and discharge. Before dosing (3 times/week), the body weights for 
all rats as well as the amount of food per cage were recorded. After 28-days, the study was 
terminated and all the surviving rats were humanely sacrificed by CO2 asphyxiation. All 
blood from the carcasses was collected via cardiac puncture and selected organs (liver, 
kidneys, lungs, spleen, brain, pancreas, gut, heart) were dissected out. The blood samples 
for each rat were divided into two sub-samples and separately subjected to hematological 
and biochemical clinical investigations (Antech Diagnostics). Some of the hematological 
parameters evaluated included; total white blood cell counts (WBC), neutrophils, 
lymphocytes, monocytes, eosinophils, basophils, total erythrocyte counts (RBC), 
hemoglobin (Hb), hematocrit (HCT), and platelet count (MPV). For serum clinical 
chemistry, the following parameters were determined: albumin, alkaline phosphatase 
(ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin 
direct, bilirubin total, creatinine (Cr), total protein, and blood urea nitrogen (BUN). 
Furthermore, the selected tissues were weighted and random samples for each organ were 
fixed in 10% neutral buffered formalin and sent for histopathological analysis.: For each 
body organ removed, the absolute organ weight (g) was used to calculate the relative organ 




HPLC-MS/MS conditions for analysis of WFA 
            The detection and quantitative analysis of WFA were performed on an Agilent 6550 
iFunnel Q-TOF with Agilent JetStream equipped with an Agilent 1290 Infinity uHPLC 
(Agilent Technologies, Santa Clara, CA, USA). For each sample run, 6 ul of sample was 
injected onto a Zorbax Extend C18, 2.1 x 50 mm, 1.8-micron column(Agilent) kept at 40 º 
C. The mobile phase was; A:  0.1% formic acid in water, B:  acetonitrile. The mobile phase 
gradient: 0-4 min 80% A to 5%A, 4-10 min held at 5%A, 10-12 min 5% A to 80%A. The 
eluant was diverted to waste for the first 4 min of the run. High-resolution spectra were 
obtained in the positive mode with a source gas temperature of 225 ºC,  sheath gas 
temperature of 375 ºC with a flow rate of 11 L/min.  The MS spectra were obtained in the 
mass range of 300-600 m/z and 90-600 m/z in the MS/MS mode. We used a fixed collision 
energy of 20 for targeted MS/MS analysis.  The precursors chosen were m/z 471 for WFA 
and m/z 361 for the IS.  For WFA, m/z 95 was used for quantification and m/z 281 and 299 
were used as qualifiers.  For the IS (prednisolone), m/z 147 was used for quantification 
with ions 325 and 343 used as qualifiers. 
Preparation of WFA Standard Solutions 
            Stock solutions of WFA and prednisolone were prepared by dissolving known 
amounts of each agent in methanol. Standard solutions of WFA and prednisolone for 
HPLC-UV analysis were diluted to final concentrations of 0.3 – 40 µg/mL while for HPLC-
MS/MS analysis, the standards were diluted to final concentrations of 0.5 – 5000 ng/mL. 
Calibrations standards were prepared by spiking known amounts of WFA in blank plasma 




 Plasma and tissue sample preparations 
             To determine WFA concentration in plasma, aliquots (100 µL)of plasma were 
mixed with 100 µL internal standard solution (100 ng/mL prednisolone) followed by the 
addition of 800 µL of ice-cold acetonitrile. The mixture was vortexed vigorously for 1 min 
and then centrifuged at 10, 000 x g for 10 min at 4 °C. The supernatants were carefully 
transferred into 2 mL silanized glass tubes and dried completely under vacuum. The 
residues were reconstituted in 100 μL of methanol, filtered and transferred to 1.5 mL HPLC 
vial for analysis of the concentrations of WFA by HPLC-MS/MS method. Similarly, to 
prepare tissue samples, about 1 g of tissue was homogenized in 3 mL of ice-cold 0.9% 
saline solution. Then, for every 1mL of tissue homogenate, 100µL of IS solution was added 
followed by the addition of 4 mL of ice-cold acetonitrile, vortexed vigorously for 1 min 
and then centrifuged at 8,000 x g for 10 min. The supernatant was carefully separated from 
the tissue debris, transferred to a new tube using a pipette and dried completely under 
vacuum. The residues were reconstituted in 1 mL of acetonitrile: water (8:2) and loaded on 
to Captiva-EMR lipid SPE cartridge (Agilent Technologies). The samples were allowed to 
flow under gravity and followed by application vacuum to dry the cartridges. The eluent 
was dried completely and then reconstituted in 100 µL of methanol prior to HPLC-MS/MS 
analysis.  
Plasma pharmacokinetics of WFA in male SD rats 
            To determine the plasma pharmacokinetic properties of WFA, male SAS SD rats 
were cannulated in the right jugular veins with polyethylene cannulae. The surgery to insert 
cannulae was performed on rats at Charles River Laboratories prior to the purchase and 
 86 
 
delivery of the rats. Following surgery, the rats were allowed to recover for one day and 
then shipped overnight to the study site. In addition, the rats were allowed one more week 
of acclimation period during which they were allowed free access to water and purified 
AIN-93M diet ad libtum. On the day of the study, rats were administered with 10 mg/kg 
(1 mg/mL in 0.1 M β-hydroxypropyl cyclodextrin) as a single bolus intravenous dose (<1 
min injection) via the lateral tail vein. Serial blood (200 µL/time point) samples were 
collected at 0, 5, 15, 30, 45, 60, 90, 120, 240, 360 and 480 minutes into heparinized tubes. 
The blood samples were processed to obtain plasma by centrifuging for 15 min at 2000 x 
g and stored at -80°C until analysis for WFA concentration using HPLC–MS/MS method. 
The concentration-time data of WFA in male SAS SD rats were subjected to non-
compartmental analysis (NCA) using Pheonix WinNonLin 8.1 software (Pharsight, CA, 
USA). The following parameters calculated: AUC0-t, AUC0-, t1/2, total plasma clearance 
(CL), mean residence time (MRT). 
 
Protein binding of WFA in SAS SD rat plasma 
The binding of anticancer drugs to plasma proteins significantly affects their 
disposition kinetics and therapeutic efficacy [112]. Therefore, the objective of this study 
was to determine the fraction of WFA bound to plasma proteins in SAS SD rat plasma. 
Protein binding of WFA in freshly collected plasma was determined by ultracentrifugation 
method for separating bound and unbound drugs using the Centrifree Ultrafiltration device 
(Millipore, USA) with a 3000-molecular cut-off. Initially, we determined that the non-
specific adsorption of WFA on to the filter membrane by dissolving known amounts of 
WFA in PBS (5% DMSO) and then determining the concentration of WFA before and after 
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centrifugation. Then, for plasma protein binding capacity, aliquots of freshly collected 
plasma (500 µL) SD rat plasma were spiked with known amounts of WFA in triplicates. 
The samples were thoroughly mixed and incubated at 37°C for 30 min. The samples were 
transferred to the Centrifree Ultracentrifugation device and centrifuged at 3000xg for 20 
min. After centrifugation, the concentration of WFA was determined in the pre- and post 
centrifugation samples (ultrafiltrate). The unbound fraction of (fu) of WFA was calculated 
as: fu = (concentration of drug in ultra-filtrate/concentration in a pre-centrifuged sample) x 
100%.  
The stability of WFA in SD rat liver microsomes 
            In this study, pooled frozen samples of SD rat liver microsomes (20 mg/ml) were 
purchased from ThermoFisher Scientific (Cat # RTMCPL). To determine the stability of 
WFA in microsomes, in a total reaction volume of 1000 µL, we used 25µL of 20 mg/mL 
commercial liver microsomes, 4 µL of drugs (0.01, 0.1 and 1 µg/ml  in methanol, 871 µL 
of 0.1 M phosphate buffer (pH 7.4) and mixed using a shaker for 5 min at 37 °C. Reactions 
were initiated by adding 100 µL of 10 mM NADPH solution to the mixture, and 100 μL of 
the reaction solution will be collected at different time points (0, 5, 15, 30, 60, 90 and 120 
minutes). At each time point, the enzymatic reactions were stopped by the addition of 4 -
volumes of cold acetonitrile to precipitate the proteins. The samples were dried under 
vacuum and reconstituted in 100 µL of methanol and analyzed for WFA concentration by 
HPLC-MS/MS. The concentrations of WFA at the start (t=0) were considered as reference 
and used to calculate percent remaining WFA with respect to t=0. The WFA/IS peak area 
ratios were plotted against incubation time curves ton estimate the in vitro half-life (t1/2). 
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The apparent intrinsic hepatic clearance was calculated as previously described [119] using 







Hepatic intrinsic clearance (CLin, app) = CLmicrosome x [microsome weight (g) /liver weight 
(g)] x [Liver weight (g)/body weight (kg)] 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 8.0 (Sandiego, CA, USA). 
Plasma concentration-time data was subjected to non-compartmental analysis (NCA) using 
the intravenous bolus model in Phoenix WinNonLin 8.1 (Pharsight, NC, USA). The 
pharmacokinetic parameters for WFA were generated from individual serial 
concentrations. The data are presented as means ± standard deviation (SD). Where 
applicable, data comparisons between two groups were made using Student’s independent-
samples t-test and one-way analysis of variance (ANOVA). Statistical significance was set 
to be p < 0.05. 
Elimination rate constant (k) = (-gradient) 
Half life (t1/2), min = 
0.693 
k 
V (µL/mg) = 
Volume of incubation (µL) 
Protein in the incubation (mg) 
Intrinsic Clearance (CLint) (µL/min/mg protein) =  





Potential sub-chronic toxicity of WFA in male SD rats 
            In this study, we evaluated the safety of repeated dosing of 4, 8, 12 mg/kg WFA to 
male SD rats for 28 days. All the rats were dosed succesifully with WFA for the 28 day 
period. None of the rats in all the 3 dose groups showed any signs of acute toxicity or 
morbidity during the study period. More importantly, no mortality of rats in either vehicle 
or experimental groups was observed at any of the 3 dose levels of WFA. Comparatively, 
there was a slight dose-dependent but non-significant increase in the overall body of rats 
dosed with WFA when compared to vehicle-treated rats over the 28-day period (Fig. 4.1a). 
This was also the case when we calculated the percent body weight gain in the groups of 
rats treated with WFA (Fig. 4.1b). However, while the percent body weight gains were 
dose-dependent, all the calculated average weekly percent body weight gains were 
statistically non-significant when compared to the vehicle-treated rats. Interestingly, data 
from the food intake studies indicated an increase food uptake among the rats that received 
WFA. Therefore, the observed dose-dependent increase in the body weights of rats that 
were treated with WFA was correlated with the increase in food intake (Fig. 4.1c). Overall, 
neither the changes in body weight gain nor food intake were statistically significant. 
            On dosing day 28 day, the toxicity study was terminated and all the rats were 
humanely sacrificed by asphyxiation under CO2 asphyxiation. Blood and body organs were 
collected at necropsy to evaluate systemic and histopathologic toxicity. There were no 
significant changes in percent body weight ratios for liver (Fig. 4.1d), lungs (Fig. 4.1e), 
kidneys (Fig. 4.1f) and spleen (Fig. 4.1g) of rats treated with WFA when compared to the 
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vehicle control group. Analysis of whole-blood samples for complete blood count (CBC) 
showed no significant changes in WBC (Fig. 4.2a), neutrophils (Fig. 4.2b), lymphocytes 
(Fig. 4.2c) or monocytes (Fig. 4.2d). Similarly, the RBC (Fig. 4.2e), hemoglobin (Fig. 
4.2f), hematocrit (Fig. 4.2g) or total platelet counts (Fig. 4.2h) were all comparable in the 
WFA treated rats and vehicle-treated group. Serum biochemical analysis did not show any 
significant changes in liver and renal function parameters. Total protein, albumin, blood 
urea nitrogen (BUN), creatinine and total electrolyte concentrations (sodium, potassium, 
chloride, and calcium) were non-signifcant (Fig. 4.3a). The enzymes AST, ALT, ALP, 
GGT were all compared in the WFA and vehicle treatment groups. Histologic examination 
of H&E sections of various organs revealed no visible microscopic changes in cellular 
architecture, evidence of tissue necrosis or inflammation in liver, kidneys, and lungs. 
Together, these findings show that repeated oral dosing of up to 12 mg/kg of WFA did not 




Fig 4.1. Effect of WFA on body and organ weight. Male SD rats were orally administered with 
vehicle (0.1 M β-hydroxypropyl cyclodextrin) or WFA (4, 8, 12 mg/kg) three times per week. (a) 
Mean weekly body weights, (b) Percent body weight gains, and (c) Mean daily food intake. 
Terminal organ weight ratios were calculated for each animal and presented as mean percent ratios 
for (d) liver, (e) lung, (f) kidneys, and (g) spleen. All data were presented as mean ± SD for each 





Fig 4.2. Effect of WFA on hematological parameters. After 28 days, rats were sacrificed under 
CO2 asphyxiation and terminal blood was collected by cardiac puncture. Mean; (a) Total white 
blood cell counts (WBC), (b) neutrophils, (c) lymphocytes, (d) monocytes, (e) total red blood cell 
counts (RBC), (f) hemoglobin (Hb), (g) hematocrit (HCT), and (h) total platelet counts. Data are 
presented as mean ± SD for each group and were compared with the vehicle. No statistically 






Fig 4.3. WFA did not cause biochemical or histological toxicity. (a) Serum was prepared 
and subjected to biochemical analysis for total protein, albumin, blood urea nitrogen (BUN), 
creatinine, AST, ALT, ALP, GGT, and electrolytes. (b) Representative photomicrographs of 





HPLC-UV and HPLC-MS/MS analysis of WFA 
            For the purposes of detection and quantification of WFA in plasma and tissues, we 
developed a highly sensitive and reproducible HPLC-MS/MS method. Previously, studies 
conducted in this laboratory [120] have used prednisolone as internal standard (IS) based 
on structural, chromatographic and extraction characteristics similarities with WFA. 
Similarly, in the present study, we used prednisolone as the internal standard. The HPLC 
chromatographic separation (1-10 µL injections) and UV detection (Fig. 4.4a), showed that 
prednisolone (RT = 5.7 min) eluted before WFA (RT=6.3 min). The maximum UV 
absorption for WFA was at 215 nm while the maximum absorbance for prednisolone was 
at 244 nm. These two compounds, WFA (Fig. 4.4c) and prednisolone (Fig. 4.4d) displayed 
linear responses in the mean peak area versus concentration curves, and the peaks for both 
compounds were saturated at 100 µg/mL. In addition, the peak area ratios (WFA/IS) were 
also plotted against WFA concentrations (Fig. 4.4e) and showed a linear relationship. The 
lower limit of detection (LLD) by HPLC- UV was 0.1 µg/mL for WFA and IS in methanol. 
            Since the main objective was to determine the levels of WFA in plasma and tissues, 
HPLC-UV was unsuitable for this analysis given the low UV absorbance of WFA (215 
nm). Therefore, we optimized a new analytical method in which we used HPLC separation 
coupled with MS/MS for detection and quantification of WFA levels. For both WFA and 
IS, we observed maximum responses in the positive MS/MS mode (Fig. 4.4b). Therefore, 
in positive MS/MS mode, we chose the m/z 471 and 361 as the precursor ions,  95 and 147 
as the quantification ions for WFA and prednisolone, respectively. The m/z 281 and 299 
ions were selected as qualifier ions for WFA while m/z 325 and 343 for prednisolone. The 




Figure 4.4. HPLC-MS/MS analysis of WFA. (a) Typical HPLC-UV chromatograpms obtained 
at 215 nm and 244 nm showing the peaks for (1) prednisolone (IS) in red and (2) WFA in green 
(volume of injection: 5 µL). (b) HPLC-MS/MS spectra for prednisolone and WFA. Standard curves 
based on peak areas were generated for (c) WFA, (d) prednisolone. (e) Using a 10 µg/mL IS, a 
standard curve based on peak area ratios (WFA/IS) was generated for WFA (0 – 40 µg/mL). (f) 






Optimization of sample pre-treatment and method validation 
            Several methods are available for the extraction of small molecules from biological 
matrices for quantitation purposes [121]. However, for each compound, there is need to 
optimize the method that results in the best extraction characteristics of the target analyte. 
In the present study, we developed and standardized a simple protein-precipitation method 
for the extraction of WFA from rat plasma and tissues. We found that for adequate and 
accurate quantitation, the sample preparation procedure required a matrix cleanup step to 
improve on the instrument sensitivity. We used 100 ng/mL prednisolone solution as the 
appropriate to monitor recoveries of WFA from plasma and tissue samples.  
            Initially, we investigated several crashing solvents to determine the best protein 
precipitation solvents. Notably, we compared acetonitrile (ACN) alone, acidified ACN (1 
% formic acid), and a mixture of ACN and methanol (MeOH) (1:1). For all these solvent 
systems, we found out that there were no major differences in the recoveries of both WFA 
and the IS. However, using ACN alone provided the cleanest supernatant and had the least 
matrix interference in MS/MS (Fig. 4.5a). Therefore, we chose ACN as the extraction 
solvent to precipitate the proteins and disrupt the protein binding of WFA in plasma and 
tissue samples. It was determined that the best extract ratio of sample solution to ACN was 
1:4 v/v. Next, when we compared the MS/MS responses of WFA in matrix versus without 
matrix and found that there was more than 70 % ion suppression, particularly for the liver 
samples. This significantly decreased the sensitivity and accuracy of the instrument and the 
detection method. To decrease on the matrix interference, we used the Captiva EMR-Lipid 
solid-phase extraction (SPE) to preferentially remove phospholipids (Fig. 4.5b). As a 

















































1. Weigh 1 g of tissue in 50 mL tube 
2. Homogenize in 3 mL 0.9 % saline solution 
3. Add 100 µL Internal Standard (IS) solution  
Step 2: 
1. Add  4 mL ice-cold ACN for 1 mL of homogenate 
2. Vortex vigorously for 1 min 
3. Centrifuge at 8000 x g for 20 minutes 
4. Transfer the supernatant to a new tube  
5. Dry under vacuum 
Step 3: 
1. Re-dissolve the residue 2 mL of ACN/H2O (8:2) 
2. Mix vigorously and centrifuge for 5 min 
3. Load on to 3 mL Captiva EMR-Lipid cartridge 
4. Allow the sample to elute under gravity  
5. Apply vacuum to dry the cartridge 
6. Dry the supernatant under vacuum 
Step 4: 
1. Re-constitute in 100 µL of MeOH 





Fig 4.6. Sample matrix cleanup using Captiva-EMR Lipid SPE (a) Representative images 
showing protein-precipitation using solvents (acetonitrile: ACN, acetonitrile + 1% formic acid; 
ACN+1%FA, acetonitrile+methanol: CAN+MeOH (1:1). (b) Matrix clean-up was done using 
Captiva-EMR lipid SPE cartridges. Standard curves for WFA spiked in (c) plasma, (d) kidney, (e) 
lung, and (f) liver matrices.    
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Metabolic stability of WFA in SD rat liver microsomes 
            In this study, the in vitro stability of WFA in microsomes was evaluated using SD 
rat microsomes at 37 °C. Briefly, 1 µM WFA was incubated with SD rat liver microsomes 
(0.1 mg total protein) in a 200µL total reaction volume. A plot of peak area ratio (WFA/IS) 
indicated a rapid time-dependent disappearance of WFA in the reaction mixture (Fig 4.7a). 
The log-transformed data (Fig. 4.7b) showed a linear relationship between the peak area 
ratios and time with a slope of -0.044. The elimination rate constant (k = - slope) of WFA 
in rat microsomes was calculated as 0.044 and the half-life was 16 min. The intrinsic 
clearance of WFA in SD rat liver microsomes was 88 µL/min/mg (Fig. 4.7c).  
 
The unbound fraction of WFA in SD rat plasma 
            To determine the extent of plasma protein binding, known amounts of WFA were 
spiked in freshly collected SD rat plasma and the unbound drug was separated from the 
bound drug by an ultrafiltration method. Initially, we determined the non-specific binding 
(NSB) of WFA to the filter membrane by dissolving WFA in PBS 0.5 µg/mL (5% DMSO). 
After centrifuging, the NSB of WFA to the Centrifree Ultrafiltration® device membrane 
was <3% (Fig. 4.7d). By comparing the concentration of WFA in plasma prior to 
centrifugation (total), retentate and the filtrate, the fraction unbound (fu) of WFA was 






Fig 4.7. In vitro stability of WFA in liver microsomes and plasma protein binding. WFA (1 
µM) was incubated with SD rat microsomes and the fraction of parent compound remaining was 
determined by HPLC-MS/MS. The peak area ratios (WFA/IS) were plotted against time on (a) 
linear and (b) logarithmic scales. (c) The half-life (t1/2) was 16 min and the in vitro intrinsic 
clearance (Clint) was 88 µL/min/mg. Plasma protein binding in fresh SD rat plasma was determined 
by ultrafiltration method. (d) Non-specific binding (NSB) was <3%. (e) Fraction unbound (fu) was 
calculated from the amount of WFA in filtrate versus total WFA in precentrifuged samples as 
approximately 5%.  
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Pharmacokinetics of a single intravenous bolus dose of 10 mg/kg WFA in SD rats 
            The pharmacokinetic properties of WFA were determined in male SD rats 
following the administration of a single intravenous bolus dose of 10 mg/kg WFA via the 
lateral vein. The concentrations of WFA in freshly collected plasma were determined by 
HPLC-MS/MS method as described in the methods section. The concentration-time plots 
of WFa in plasma (Fig 4.8a) demonstrated a rapid decline in the concentration of WFA 
with time. The mean concentrations of WFA in plasma rapidly fell below the limit of 
quantification within 2 h after dosing. The log-transformed concentration data (Fig. 4.8b) 
showed a linear relationship with time. The pharmacokinetic parameters of WFA were 
estimated using Phoenix WinNonLin 8.1 (Fig. 4.8c). The maximum plasma concentration 
was 907 ng/mL and was observed at the first sampling time point of 5 min after dosing. 
The last measurable concentration, Clast, was 14 ng/mL at 2 h, with an AUClast of 15960 
ng/mL*min and the AUC0-inf was 16709 ng half-life (t1/2) of WFA was 37 mins. The 























Fig 4.8. Plasma pharmacokinetics of WFA in male SD rats. Plasma concentration (ng/mL) 
versus time curve profile of WFA following a single bolus intravenous injection of 10 mg/kg WFA 
in male SD rats. (a) Linear, and (b) Log-linear concentration versus time curves. (c) Non-
compartmental analysis was perfomed using phoenix WinNonLin 8.1 to determine 
pharmacokinetic parameters.  
  
Pharmacokinetic Parameter Value 
Cmax (ng/mL) 907 
Tmax (min) 5 
Clast (ng/mL) 14 
AUC0-t (ng/mL* min) 15960 
AUC0-inf (ng/mL* min) 16708 
Extrapolation (%) 4.3 
t1/2 (min) 37 
CL (mL/min/kg) 598 
AUMC0-t (ng/mL * min *min) 352613 

















































           Many of the cytotoxic drugs used in the systemic chemotherapy of NSCLC require 
high doses to achieve clinically efficacious concentrations [13]. Traditionally, the dosage 
calculations for anticancer drugs are based on body surface area (BSA) which is derived 
from the body weight and height of patients [113]. However, this approach has proven 
inadequate and fallacious since several studies have shown that factors such as protein 
binding, metabolism, and clearance of drugs significantly affect the clinical efficacy of 
cancer treatment [112]. Moreover, cancer patient populations are often highly complex and 
varied in terms of age, presence of comorbidities or organ impairments [3]. In the current 
era of personalized medicine [12], dosing of patients with such highly toxic agents requires 
precise knowledge on the disposition characteristics of these agents. Today, the treatment 
guidelines for NSCLC involve multi-drug combinations which are administered via 
complex dosing schedules and sequences. Since there are limitations on the conduct of 
pharmacokinetic studies in cancer patients, the pharmacokinetic properties of most anti-
cancer drugs used currently are poorly characterized. Therefore, to better predict the 
clinical efficacy of future cancer treatments, the potential anticancer agents must be well 
characterized in the preclinical setting for their toxicity and pharmacokinetic properties 
before studies are initiated in humans [9, 16].  
            Several published studies have demonstrated the potential therapeutic efficacy of 
WFA against multiple cancer types [22]. However, there is still very limited data describing 
the toxicity and pharmacokinetic properties of WFA to enable the design of appropriate 
doses and dosing schedules for clinical studies. As such, for several decades, the anticancer 
testing for the therapeutic efficacy of WFA is limited to preclinical studies. In addition, 
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another major challenge to the study of the pharmacokinetics of WFA has been the lack of 
reliable, accurate and reproducible analytical methods for the detection and quantification 
of WFA in biological matrices. To address these challenges, we investigated the potential 
repeated dosing toxicity and the single-dose preclinical pharmacokinetic profile of WFA 
in male SD rats. Analytically, we have developed a highly sensitive HPLC-MS/MS method 
for the detection and quantification of WFA in plasma and tissues. In our studies, we have 
successfully applied this method to study the pharmacokinetics of WFA in males SD rats.  
            Ealier studies investigating the toxicity of WFA in experimental animals have been 
based on observation of animals dosed with standardized extracts of W. somnifera. 
Notably, studies have shown that alcoholic extracts of W. somnifera extract (up to 2000 
mg/kg) were non-toxic to Wistar rats after 14-days repeated oral dosing [122]. Similar 
studies have reported no signs of systemic or histological toxicity following repeated sub-
chronic dosing of WFA in mice [123, 124]. Although it is evident that extracts containing 
WFA have been evaluated for their toxicity, the extracts used in these studies contained 
<5% total WFA (% w/w). Contrastingly, we have investigated the potential toxicity of pure 
WFA (>95% purity) in male SD rats. In agreement with previously published studies, the 
findings presented here show that orally administered WFA is essentially non-toxic to male 
SD rats. While we observed a slight dose-dependent increase in body weight in the groups 
of rats receiving WFA, these changes were nonsignificant. Moreover, evaluations of the 
average food intake indicated that the observed body weight gains were correlated with 
higher food intake. More importantly, systemic data did not reveal any evidence of bone 
marrow suppression since parameters such as total RBC, WBC, Hb, and HCT were all 
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comparable to vehicle-treated rats. Therefore, the doses (4, 8, and 12 mg/kg) of WFA that 
we used in the present study were generally well tolerated and safe in male rats.  
              One major hindrance to the study of the pharmacokinetics of WFA has been the 
lack of appropriate analytical methods.  In literature, there are a few HPLC and HPLC-
ESI-MS/MS methods for the detection of have been published [125-127]. It has been 
reported that these methods could detect and quantify WFA in plasma up to a lower limit 
of 50 ng/mL. Unfortunately, we failed to reproduce these methods as many did not include 
sufficient experimental details. Whereas there are methods for detection of WFA in plasma, 
limited information is available for the detection of WFA levels in tissue organs such as 
liver, lungs, and kidneys. Moreover, during our preliminary studies, we compared the effect 
of the matrix from plasma to that of other tissues and found that tissue matrices, especially 
from the liver significantly suppressed ionization and subsequent detection of WFA by LC-
MS/MS conditions.  Therefore, while the authors [125] argue that the published methods 
could successfully be applied to quantify WFA in plasma, the methods were not applicable 
to tissues.  Recently, studies done and published from this laboratory reported a liquid-
liquid extraction method for the detection and quantification of WFA in tissues. Along the 
same lines, we have made improvements to this method by adding a solid phase matrix 
clean-up step instead of liquid-liquid sample preparation.  
             During our preliminary sample preparation studies, we investigated multiple 
protein precipitation solvents to determine the most suitable of WFA. Though sample 
preparation was adequate for both methanol and acetonitrile, the supernatants from samples 
prepared with methanol were found to be turbid and the protein pellets were quite unstable. 
Therefore, sample preparation with methanol (100% or 50%) was deemed unsuitable for 
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the extraction since it produced significant matrix interference with the analytical 
conditions. On the other hand, acetonitrile produced much better response and was selected 
as the crushing solvent for sample preparation in subsequent studies. Further, in our 
analysis, whereas protein precipitation with acetonitrile eliminated most proteins, there was 
still significant interference on the ionization of WFA from lipids and phospholipids in the 
extracted samples. To address this challenge, we examined several SPE methods for matrix 
removal and found that the Captiva EMR-lipid cartridges (Agilent Technologies), which 
are specially made for the removal of phospholipids. Intriguingly, this step significantly 
improved the sensitivity of LC-MS/MS detection conditions and by applying a 10-fold 
concentration of the original samples (by reconstituting samples (1 g tissue or 1 mL 
plasma) in to 100 µL final volume, we improved the detection of WFA to up to 5 ng/g of 
tissue or 1 ng/ml of plasma. Our recovery of both WFA and internal standard was greatest 
from plasma samples (>80%) and lowest in liver samples (approx. 75%).  
             After developing the analytical method, we next investigated the pharmacokinetic 
properties of WFA in SD rats. Previously, studies conducted in mice have investigated the 
pharmacokinetics of WFA [31, 128]. However, whereas plasma pharmacokinetics were 
investigated after oral administration in these studies, no data on protein binding capacity 
or metabolic stability in microsomes are reported. Therefore, in our studies, we investigated 
both the plasma protein binding capacity and metabolic stability of WFA in liver 
microsomes in SD rats. Our data show that WFA displays a high protein binding capacity 
in rat plasma resulting in a with a very low fraction unbound (fu). Since pharmacokinetic 
properties such as hepatic metabolism, clearance, and volume of distribution are heavily 
dependent on to the unbound fraction of drugs there is a significant potential of WFA to 
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interact with drugs that show similar protein binding characteristics. In addition, WFA 
displayed a high intrinsic hepatic clearance (>80 µl/min/mg) indicating that the liver plays 
a critical role in the clearance of WFA from the body. Further, based on our plasma 
concentration-time data, we show that WFA has linear pharmacokinetics in SD rats. 
Following intravenous bolus administration, there was very rapid distribution and 
clearance of WFA from plasma. There was a high volume of distribution greater than the 
total body water indicating the extensive distribution of WFA in tissues. Since 
concentrations of WFA fell below the limit of detection in 2 h, it appears slow intravenous 
infusions would be the best mode administration. The observed short terminal plasma 
t1/2 was in tandem with the observed rapid intrinsic clearance of WFA in rat microsomes 
indicating the potential role of the liver in the clearance of WFA. Since urine was never 
collected in the present studies, we did not determine the renal clearance of WFA. 
Nonetheless, our observed plasma pharmacokinetic parameters were similar to those 
obtained in mice after intraperitoneal and oral dosing of WFA.  
               In conclusion, WFA is a promising antitumor agent for the treatment of multiple 
types of cancers. In the present study, we have investigated the potential oral toxicity and 
preclinical pharmacokinetic properties of WFA SD rats. We conclude that oral dosing of 
up 12 mg/kg of WFA was safe and well-tolerated without any signs of gross or systemic 
toxicity in male SD rats. Further, WFA displays a high protein binding capacity to plasma 
proteins indicating a potential for drug-drug interactions. Moreover, WFA displayed rapid 
clearance in liver microsomes and plasma indicating that slow continuous infusion would 
be the most appropriate mode of administration. Further studies to determine the tissue- 




OVERALL DISCUSSION, SUMMARY, AND CONCLUSIONS 
            Lung cancer remains the leading cause of cancer-related deaths among both men 
and women worldwide, and in the United States. NSCLC contributes to 85-90% of all lung 
cancer cases and has an overall survival rate of 15% after five years. The major reason for 
the dismal prognosis of NSCLC is that 60-70% of patients are diagnosed when the disease 
is at an advanced stage. As such, the tumors in many NSCLC patients are not amenable to 
curative surgery and most of the patients succumb in less than one year after diagnosis. 
Thus, systemic chemotherapy remains the only viable treatment option in the neoadjuvant, 
adjuvant or palliative setting for advanced NSCLC.  
            Recently, there has been a paradigm shift in the treatment approaches for advanced 
NSCLC. This was mainly prompted by the landmark discoveries of molecularly targeted 
drugs and immunotherapies for NSCLC. However, despite these advancements, only 
marginal improvements in progression-free survival but not overall survival have been 
reported. Besides the high cost of therapy, targeted and immunotherapies only benefit 
select groups of patients that fit a strict inclusion. Therefore, for the majority of NSCLC 
patients, systemic treatment involves the administration of multiple cycles of high doses of 
cytotoxic agents. Currently, cisplatin (cis-Pt) alongside paclitaxel (PAC) is the front-line 
treatment regimen in the clinic for stage IIIB-V metastatic NSCLC [11, 129]. However, 
chemoresistance, metastasis, and dose-limiting toxicities limit the therapeutic efficacy to a 
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maximum of 14 months. In this doctoral thesis, we leverage the ability of WFA, a highly 
efficacious plant-derived steroidal lactone to enhance the chemotherapeutic efficacy of 
PAC against NSCLC. The main hypothesis was that WFA alongside PAC is a highly 
synergistic approach, which shows greater antitumor efficacy than the current platinum-
based chemotherapies. To test this hypothesis, we designed experiments to; (1) explore the 
synergistic combination of PAC and WFA against human NSCLC cells, (2) determine the 
effect of WFA on epithelial to mesenchymal transition (EMT), (3) determine the safety 
and pharmacokinetic properties of WFA in experimental animals.  
             To demonstrate the in vitro antitumor efficacy, we used two human NSCLC cell 
lines, H1299 (large cell carcinoma) and A549 (adenocarcinoma). Firstly, we showed that 
that WFA alone was active against the growth and proliferation of both H1299 and A549 
cell lines. The effects of WFA were both doses- and time-dependent, with median 
inhibitory concentrations in the sub-micromolar range. As reported previously [130, 131], 
WFA increased the production of reactive oxygen species (ROS) and induced cellular 
apoptosis in NSCLC cells. The cytotoxic effects of WFA blocked the thiol donors 
dithiothreitol (DTT) and N-acetyl cysteine (NAC). Therefore, we conclude and provide 
evidence for the hypothesis that WFA induced apoptosis in NSCLC via thiol-dependent 
mechanisms [130]. Next, we performed multiple drug combination studies consisting of 
two drugs of either PAC, cis-Pt or WFA to determine the most efficacious combination 
against cellular proliferation. Our data show that the combination of PAC+WFA was more 
efficacious than PAC+cisPt, or cisPt+WFA. There was a dramatic increase in the potency 
and efficacy of PAC when combined with WFA at 1:40, 1:20 and 1:10 combinatorial ratios, 
respectively. Importantly, pretreatment of cells with WFA increased the synergistic effects 
 110 
 
of PAC and WFA indicating a chemosensitizing effect of WFA on NSCLC cells to 
standard chemotherapeutic drugs. Together, the data presented demonstrate that the use of 
WFA alongside PAC is a very attractive and viable alternative therapeutic strategy, and 
provides a strong rationale for further testing of this combination in animal models and 
clinical studies.  
             Today, > 90% of deaths in NSCLC are directly attributable to chemoresistance and 
metastasis [13]. This prompted us the investigate whether WFA alone or in combination 
with PAC targets chemoresistance in NSCLC. First, we used both drug-sensitive and drug-
resistant cells to determine the effects on cellular proliferation and mechanisms of drug 
resistance. Interestingly, our data show that PAC-resistant (TR-A549) cells were cross-
resistant to cis-Pt but not to WFA. These cells overexpressed the MDR1 protein, an 
indicator that increased drug efflux was the main mechanism of resistance [73]. Further, 
PDL-1 expression was upregulated while E-cadherin was downregulation suggesting a 
strong link between EMT, drug resistance and immune evasion in NSCLC. Thus, it appears 
that the resistance of TR-A549 cells to PAC was associated with an upregulation of drug 
efflux mechanisms, immune evasion, and EMT. When xenografted in athymic nude mice, 
WFA significantly inhibited tumor growth  PAC-resistant cells. Moreover, WFA treated 
downregulated the expression of MDR1 in PAC resistant cells. Mechanistically, WFA 
inhibited EMT induction via the regulation of smad2/3 and NF-κB signaling in a dose- and 
time-dependent manner. In summary, these findings strongly suggest that WFA is highly 
active against both drug-sensitive and drug-resistant NSCLC cells and its ability to inhibit 
EMT in NSCLC cells demonstrates the potential of WFA to prevent or delay the emergence 
of chemoresistance and metastasis in NSCLC during treatment. 
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            Also, while multiple studies have reported the therapeutic efficacy of WFA, there 
is very limited data on its potential toxicity and pharmacokinetics. In this thesis, we 
examined the toxicity of WFA in male SD rats. Previously, some studies [122] have 
indirectly investigated the toxicity of WFA in mice and rats by administering standardized 
alcoholic extracts of W. somnifera. However, the limitation was that the content of WFA 
in these extracts was very low (<1% w/w), and considering the chemical complexity of W. 
somnifera extracts, it is not possible to delineate the effects of WFA from other compounds. 
In contrast, we have evaluated the potential toxicity of repeated oral dosing of highly pure 
WFA (>95%, HPLC) and found that WFA did not cause any signs of toxicity in a 28-day 
study. In our study, up to 12 mg/kg of WFA was given as three doses per week via oral 
gavage and did not cause any changes in hematological, biochemical or histopathological 
parameters. Next, a highly sensitive, reproducible and robust HPLC-MS/MS method for 
the detection and quantification of WFA in plasma and tissue samples was developed. In 
this method, WFA from plasma or tissues is extracted by simple liquid-liquid extraction 
followed an SPE matrix cleanup step using Captiva-EMR lipid removal cartridges. While 
other methods have been previously published [125], all these were not suitable for analysis 
of WFA in tissue by LC-MS/MS due to significant ion suppression. Using our method, the 
sensitivity of LC-MS/MS was increased up to 80% for the detection of WFA in tissue 
samples.  
            To study the pharmacokinetic properties of  WFA, we determined the plasma 
protein binding capacity, in vitro clearance in microsomes, and the plasma pharmacokinetic 
properties of WFA in male SD rats. Using in vitro methods, we demonstrate that WFA 
displays a high plasma protein binding (>95%) capacity as measured by ultrafiltration. 
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Interestingly, when incubated in liver microsomes, there was a high intrinsic hepatic 
clearance of WFA (Clint: 88 µL/min/mg). In male SD rats, WFA displayed an instant 
distribution phase and rapid clearance from plasma. Following a single bolus dose of 10 
mg/kg, the levels of WFA were below the limit of detection within 2 h. Together, these 
findings suggest that WFA has a high volume of distribution in tissues, a high protein 
binding capability to plasma proteins and hepatic clearance is the main elimination route 
for WFA. Overall, our studies demonstrate that WFA is well tolerated and safe following 
repeated oral dosing in rats. We developed a detailed method for the determination of WFA 
in biological matrices and have used this method to study the pharmacokinetic properties 
of WFA in SD rats. 
              In future studies, it is important that the synergistic effects of PAC and WFA are 
validated in animal studies before clinical studies can be initiated. It is well known that 
PAC treatment induces chemoresistance and metastasis mechanisms in NSCLC cells. 
Therefore, we recommend that studies be conducted to investigate whether WFA when 
used alongside PAC, can prevent the emergence of chemoresistance and metastasis in 
NSCLC. Furthermore, both PAC and WFA show high protein binding and clearance in 
liver microsomes. Therefore, it is important to study the pharmacokinetics of PAC+WFA 
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